subject index for volume 33 · nephropathy, captopril and diltiazem (abst) 382 nephrosis, protein...
TRANSCRIPT
Subject Index For Volume 33
Abdominal aneurysm, renal injury (abst) 623Ablation
anemia lessens hypertension and proteinuria (abst) . . . 375deep nephrons (abst) 374
AcetatecAMP (abst) 219succinate, effects in dialysis (abst) 228
Acetazolamidediabetic nephropathy (abst) 209kinetics of anion exchange inhibitor (abst) 406pH, transport (abst) 157
Acidamino, keto, disturbances of metabolism in RF (abst).. 139amino, keto in diet for CRF (abst) 138
Acid-baseabnormalities in cardiopulmonary arrest (abst) 185status and dialysis symptoms 24:S-l17status in ESRD (abst) 246
AcidificationCsA in heart transplant (abst) 440IMCD adaptation (abst) 398proton locating ATPase 767
Acidosisacidification defect in distal renal tubular (abst) 130ammonium excretion (abst) 183carbicarb vs. bicarbonate in treatment (abst) 407flow rate determines bicarbonate reabsorption (abst). .. 404GLA protein and bone films in HD (abst) 232glucose reabsorption, hyperglycemia (abst) 201hyperchioremic (abst) 1040interaction of glutamine and glutathione (abst) 390metabolic, adaptation in BLM (abst) 405metabolic, H-ATPase (abst) 404metabolic, HCO3 reabsorption (abst) 404metabolic, K depletion (abst) 405Na dependent, distal acidification (abst) 194
phosphoenolpyruvate carboxykinase (abst) 177
respiratory (abst) 402stimulates endocytic activity in CCD (abst) 406
Acinetobacter peritonitis (abst) 246Actetate
muscle high energy metabolites during HD (abst) 240Acute Hantavirus nephropathy (abst) 356Acute pancreatitis diagnosis (abst) 183Acute renal failure
after transplantation, perfused allograft (abst) 450
aminoglycoside nephrotoxicity 900analgesic drugs (abst) 352Aug II augments hypoxia (abst) 354artery reconstruction (abst) 136CAVH 24:S-159CAVH in 100 patients (abst) 757clearance of calcitriol 530coagulation defects in uremia 24:S-l3deferoxamine (abst) 363djenkolic acid induced (abst) 359DNA synthesis and polymerase activity (abst) 623endotoxemic ARF, role of PAF (abst) 358
xl
focus of tissue necrosis and gentamicin 84glycerol induced, HgCl2 nephrotoxicity (abst) 352histopathology of ischemic (abst) 366hydroxyl radical in glycerol induced (abst) 368hypoperfusion, gentamicin (abst) 357induction and prevention of media-induced 699mannitol induced (abst) 188
methylguanidine (abst) 371
nephrotoxic, loop diuretics (abst) 364newborn, treatment (abst) 226plasma exchange in multiple myeloma 1175post-ischemia (abst) 369reactive oxygen species do not mediate ischemic
(abst) 370renal recovery and survival (abst) 238requiring dialysis (abst) 756saline loading in uranium-induced 942theophylline use in post-ischemic 24urine sediment, childhood (abst) 1041vasa recta blood flow (abst) 369proto-oncogene expression (abst) 152
Acute renal insufficiencytheophylline prevents hypoxemia-induced changes . .. 1078
Acute tubular necrosisclearance of calcitriol 530culture of cells from urine (abst) 364HgCl2 and K2Cr2O7 induced (abst) 365
AdenosineAl analog, TGF (abst) 263analogues, tubuloglomerular feedback (abst) 413cGMP a second messenger in renin inhibition 798deaminase, ischemia (abst) 367nucleotides in azotemic rabbits (abst) 382receptor localization (abst) 256renal function and vasa recta blood flow (abst) 276triphosphate, thymidine incorporation (abst) 3892C1, cAMP production and Na transport (abst) 419
Adenylate cyclaseAVP in aging human CT (abst) 290lithium (abst) 265monoclonal antibody 543mutations in Gs alpha (abst) 166
ADHglycerophosphoryicholine (abst) 255inhibition, diuresis (abst) 432
Adhesive glycoproteinsfibronectin (abst) 154
ADPKDadenocarcinoma, chronic HD (abst) 1040continuous tissue culture (abst) 191
cystic kidneys 610diphenyithiazole 1130genetic marker for diagnosis (abst) 625hyperuricemia in (abst) 211influence of sex on liver disease (abst) 196
screening protocol (abst) 191
Adriamycininduced NS (abst) 261
Subject Index: Vol. 33 xli
nephropathy, captopril and diltiazem (abst) 382
nephrosis, protein restriction (abst) 380Aerobics in obese Zucker rats (abst) 326
Agecatecholamaine receptor binding 1073desensitization to PTH (abst) 348diet and sex response to immune injury 561
disease diagnosis, IgA (abst) 196
quality of life of old dialysis patients (abst) 758reduction in cytosolic Ca2 response (abst) 338
Agenesis vs. nephrectomy (abst) 143, 195AIDS
ARC and nephrotic syndrome (abst) 210associated nephropathy not in San Francisco (abst) . . . 202FSGS during (abst) 1041HIV antibodies in Danish dialysis patients (abst) 756HIV associated focal, segmental sclerosis (abst) 330HIV infections in HD (abst) 230HIV testing in chronic HD (abst) 235HIV transmission during HD (abst) 233hyponatremia, ARC (abst) 211nephropathy as initial manifestation (abst) 205peritonitis in HIV infected CAPD patients (abst) 245rapid renal failure (abst) 198
Alanine flux, CRF (abst) 395Albumin
extrarenal complications in nephrotic syndrome 1184
gene transcription (abst) 156
glycation of 673hemodynamics of excretion (abst) 434mild charge modification, excretion (abst) 433mild charge modification on excretion (abst) 1039optimal determination of excretion in diabetics
(abst) 214progressive decrease of in CAPD (abst) 757synthesis with dietary protein restriction (abst) 379synthesis, dietary protein (abst) 378
Albuminuriainsulin-dependent diabetes mellitus 100
lysozymuria in Heymann's nephritis 787protein or enalapril (abst) 377
Alcohol abuse, mes IG deposition (abst) 385Aldose reductase
sorbitol in maintaining the medullary intracellularmilieu 635
AldosteroneADH, electrolytes (abst) 283
ATPase activity (abst) 278
biochemical pathway of (abst) 276
chronic acid loading (abst) 401
high potassium intake (abst) 270
K adaptation (abst) 427K and kaliuresis after acute loading of K (abst) 1037mechanism of increase in K conductance (abst) 429PCO2 enhance vanadate RB absorption (abst) 423voltage gated Ca currents in adrenal cells (abst) 291
19-nor, urinary excretion (abst) 273
Alfacalcidol, Ca iones (abst) 334Alkali secretion into urine (abst) 399Alkaline phosphatase in kidney (abst) 176Alkalosis
acute respiratory, PG (abst)calcium retention (abst)chloride depletion in KCl depletion (abst)chloride depletion metabolic (abst)
chronic neutral phosphate infusion (abst) 401distal nephron maintains chloride-deplete (abst) 409
PhCo3 in K-depletion (abst) 402response to bumetanide (abst) 200
Allograftbiopsies compared (abst) 440cadaver donor age and survival of (abst) 450
CD4+ specific suppressor cell (abst) 443
dietary protein restriction, CsA, rejection (abst) 1038
dysfunction, eosinophils (abst) 453factors influencing function (abst) 454glutathione transferase in urine 571
inflammatory cells, /32M and thromboxane (abst) 442long term predictors of survival (abst) 448monotored by plasma neopterin levels (abst) 453serum 11-2 (abst) 453survival determinants (abst) 444tolerance (abst) 447
Allopurinol, ischemia (abst) 396Alpha human natriuretic peptide
response to in CRF (abst) 287
Alpha-adrenergic agonist, 02 (abst) 392
Alpha-galactosidase, Fabry's (abst) 182
Alpha-hydroxylaseactivity, PTH (abst) 338
vitamin D3 (abst) 336Alpha- 1 -adrenergic
stimulation of diacyglycerol production (abst) 388
Alpha2 adrenoceptormediated vasoconstriction (abst) 414
Aluminumbone disease in children on CAPD or CCPD 975
erythropoiesis, deferoxamine (abst) 215hair and serum, in children with CRF (abst) 139
improvement in microcytic anemia (abst) 215induced osteomalacia, PTH (abst) 343infusion on PTH release (abst) 336iron overload in chronic dialysis 24:S-163microcytic anemia (abst) 349
phosphate 24:S-172phospholipid content of BBMV (abst) 350PTH in transplantation (abst) 346PTH secretion in HD, Ca (abst) 231
PTH secretion, Ca (abst) 337
removal, membranes compared 24:S-171resistance to recombinant human erythropoietin
(abst) 240serum, monitoring in HD (abst) 218vitamin D3 increases plasma, HD 24:S-l75
Ambulatory peritoneal dialysisintermittent (abst) 244
Ambystomadiluting segment (abst) 419
PT, Cl— transport (abst) 423Amikacin toxicity in rat neonates 36Amiloride
binding site, lysine group, NaIH antiporter (abst) 401
Ca absorption by (abst) 341
sensitive urea transport (abst) 4335-(N-methyl-N-isobutyl) (abst) 399
Amino acidinduced rise in hemodynamics, glucagon and PGE .. . 1147
metabolism, hepatic glucose, uremia (abst) 356sequences in mouse and bovine ACE homology 652
transport (abst) 432
401338402400
xlii Subject Index: Vol. 33
uptake, adaptive response to (abst) 417Aminoglycoside
and ARF 84nephrotoxicity 900
Aminonucleoside nephrosistubulointerstitial nephritis 14
Ammoniaproduction by perfused PT (abst) 405
Ammoniagenesisgamma glutamyltransferase, PAH (abst) 397gamma-glutamyltransferase (abst) 391glutamine, benzoate (abst) 392pH and NH1 metabolism in LLC-PKI cells (abst) 394PTH (abst) 389
Ammoniagenic pathways, 15N (abst) 167Ammonium
ion absorption by TAL (abst) 400ionic exit from tubule (abst) 407
Amphotericin Bcoccidioidomycosis(abst) 193toxicity (abst) 360
Amyloid arthropathy, RDT (abst) 626Amyloidosis
A characterization (abst) 330asymptomatic dialysis patients (abst) 236biocompatibility phenomenon of HD 24:S-35dialysis associated with long-term HD (abst) 234dialysis related 24:S-32HD associated (abst) 231
Analgesicdrugs, tubular damage (abst) 352nephropathy, biopsies in (abst) 145nephropathy, proteinuria is glomerular (abst) 141syndrome (abst) 136
Analogs of vitamin D3 (abst) 339Anaphylatoxin adsorption, HD (abst) 226Androgen
regulation of antiotensinogen messenger RNA (abst). . . 262Anemia
correction in chronic HD (abst) 237correction in hemodialysis (abst) 189erythropoiesis and erythropoietin blood levels (abst). . . 372erythropoietin, hemoglobin (abst) 217ESRD 983exercise capacity in HD (abst) 206human erythropoietin, hemodialysis (abst) 204hypertension and proteinuria in ablation (abst) 375microcytic, Al induced in HD (abst) 215peroxidation of polyunsaturated fatty acids (abst) 624recombinant human erythropoietin (abst) 232rHuEPO in HD (abst) 623risk factor in kidney biopsies (abst) 202
Angioplasty in elderly, RF (abst) 203Angiotensin
pressure-natriuresis relationship (abst)renin in hybridization (abst)renin, gene expression in (abst)tubuloglomerular feedback responses (abst)urinary excretion a marker of renal production
(abst) 1036Angiotensin converting enzyme
acute inhibition of (abst) 757cDNA isolation (abst) 150eliminatin of hippuran in RAS (abst) 760enalapril in diabetic nephropathy (abst) 178
hydroosmotic action of AVP (abst) 284inhibition, arterial stenosis (abst) 306inhibition, renal artery stenosis 1038inhibitor, suppresses growth of cells (abst) 296inhibitor, urea excreation (abst) 196partial protein sequence of mouse and bovine 652protein restriction, nephrosis (abst) 188reversible depression of Na,K-ATPase (abst) 303role in glomerulo-tubular balance (abst) 421
Angiotensin Iconverting enzyme, GFR (abst) 259
Angiotensin IIasymmetric reduction of receptor sites (abst) 304AVP in vascular smooth muscle cells (abst) 151
blockade reduces proteinuria (abst) 383causes formation of PAF (abst) 278CE!, reduced renal mass (abst) 384control of early proximal acidification (abst) 398disordered receptor regulation, diabetes (abst) 302down regulation of receptors in VSM (abst) 288hypertension (abst) 382Na reabsorption (abst) 129PGI on hemodynamics (abst) 413phospholipase A2, GTP binding protein (abst) 154platelet receptors, HD (abst) 230receptors and eicosanoid production (abst) 257sorbinil (abst) 380streptozotocin-induced diabetes (abst) 380thromboxane responses to (abst) 30812-lipoxygenase products (abst) 173
Angiotensinogenproduction by PTC (abst) 291role in glomerulo-tubular balance (abst) 421
Anionarginyl and histidyl groups (abst) 438
Anion exchanger, band 3 (abst) 168Anionic sites in MGN (abst) 627Ankyrin, spectrin and Na,K-ATPase (abst) 167Anoxia
alterations in Ca compartmentation (abst) 361cytosolic free Ca in renal damage (abst) 359metabolic responses to, hypoxia (abst) 390
Anti-GBM diseasequantitation oLantibody (abst) 135
Antibodiesand lectin staining for glomerular cells (abst) 159anti-endothelial cell, IgAN (abst) 334anti-GBM, anti-neutrophil cytoplasm, nephritis
(abst) 329anti-heparan sulfate proteoglycan (abst) 320anti-phospholipid, lupus nephritis (abst) 328circulating DNA and lupus nephritis 487epitope specific induction of proteinuria by 831
etylendioxid IgE (abst) 755glomerular, in human anti-GBM disease (abst) 135
Heymann nephritis antigen (abst) 251HLA removed in dialysis (abst) 4431gM anti-neutrophil, pulmonary hemorrhage (abst) .... 328immune complexes formation (abst)immune deposits in cryoglobulinemia (abst)induced mesangial cell lysis (abst)monoclonal anti-idiotype, DNA (abst)monoclonal, myeloma cast nephropathy (abst)monoclonal, nucleated cells in urine sediment (abst).new antigen system in progressive RF (abst)
411169163411
312626327199328332333
Subject Index: Vol. 33 xliii
noncationized, immune complexes (abst) 315
polyreactive anti-DNA, lupus nephritis (abst) 331serological diagnosis of Wegener' s granulomatosis
(abst) 760SGP-1151107, induction of proteinuria 818
Antidigoxin antibody, Na,K ATPase (abst) 383Antidiuresis
euglycemic insulin, chloride handling (abst) 271Antidiuretic hormone
nephron function by micropuncture (abst) 141
Antigenantibodies interact with, glomerular epithelial (abst) . . . 314binding, surface charge distribution (abst) 310clearance of immune complex (abst) 320GP600, glycoproteins in Heymann nephritis (abst) 164monoclonal anti-DNA antibodies (abst) 323non-GBM glomerular capillary wall, antibody to
(abst) 144
secreting epithelial cells (abst) 317streptococcal nephritogenic, complement activation
(abst) 144tubular, associated renal disease, injury (abst) 131
Antioxidant therapy, ischemia (abst) 353
AntiportNa/H and sodium chloride (abst) 157racial difference (abst) 297
system, polarized (abst) 406Antiporter
activity, renal nerves (abst) 420enhancement of Na-H in chronic hypercapnia (abst). . . 407Na-H, phorbol-ester stimulates(abst) 428genetic marker for diagnosis (abst) 625
Apical membrane activation, cAMP (abst) 427APKD
anatomy of renin-secreting cell 1084
dietary protein (abst) 315histochemical studies (abst) 333linked DNA marker (abst) 184natriuretic response to volume expansion (abst) 211progressive, liver lesions in (abst) 192
reducing cyst volume (abst) 181
surgical anatomy of liver (abst) 202
Apoferritin, ICGN (abst) 314Arachidonic acid
diabetic rat (abst) 393P-450 (abst) 162
Arginine vasopressinACE inhibitors (abst) 284ADH and urea therapy (abst) 130AT! desensitization (abst) 151
bombesin (abst) 282
cAMP, pertussis toxin, somatostatin inhibition 536
dopaminergic stimuli (abst) 283gene expression in heart failure (abst) 270gene regulation in HBR (abst) 285
glucose uptake and oxidation (abst) 390286267306
mesangial cell replication (abst)14,15 dihydroxyeicosatrienoic acid (abst)
Arterial stenosis, ACE (abst)Arterioles
vasopressin selectively contracts (abst) 262Arteriovenous fistulas (abst) 761
Arteryreconstruction in renal failure patients (abst) 136
Arthritisoverview of pediatric nephropathology.
Artificial atria, ventricles, ANF (abst) . .
Ascitesintractable, ascitic ultrafiltration (abst)
Ascitis, paracentesis (abst)Aspirin, lupus nephritis (abst)Atenolol, exercise, hypertension (abst) .Atherogenic role of vitamin D3 (abst)Atherosclerosis, FSGSATP
ion transport systems (abst) 173ATPase
aldosterone (abst) 278
Ca absorption (abst) 347C1 dependent H (abst) 159oxygen free radical (abst) 1038
proton locating 767proton translocating in IMCD (abst) 408uremic factor inhibits RBC (abst) 222
Atrial natriuretic factorAng II, phosphoinositide changes (abst) 253antagonizes PGE2 release (abst) 279calves, artificial atria (abst) 290
captopril, hypertension (abst) 277cerebrospinal fluid concentrations (abst) 256clearance receptors (abst) 279
CyA nephrotoxicity (abst) 356heart failure (abst) 262high-output heart failure 656
hypotensive hemorrhage (abst) 369mineralocorticoid escape (abst) 430myocytes in fish (abst) 253Na excretion (abst) 284natriuresis (abst) 258osmotic water permeability (abst) 278plasma concentration in pregnancy (abst) 140poorly controlled diabetes (abst) 254post-ischemic acute failure (abst) 363
pregnancy (abst) 257
saline-expanded dogs (abst) 266salt adaptation in fish (abst) 289sodium retention during heart failure (abst) 272valsalva maneuver (abst) 2691-30 and 31-67 circulate in human (abst) 284
Atrial natriuretic peptideANF, dopamine, renal ischemia (abst) 259anti-ANP antibody, congestive heart failure (abst) 253augments excretion of Pi and Na (abst) 279blood glucose in insulin-dependent diabetes (abst) 759cirrhosis (abst) 257CRF (abst) 263
disappearance in dogs (abst) 275
down regulation of receptors (abst) 287
enalapril (abst) 1038
ESRD, periodic determinations (abst) 287gentamicin induced ARF (abst) 366GFR in hydronephrosis (abst) 358head out water immersion, cirrhotics (abst) 272hemodialysis in chronic uremic patients (abst) 758hypercalciuria (abst) 340hypervolemia in nephrotic humans (abst) 281
ligand, BP (abst) 271molecular forms in plasma and urine (abst) 201Na urinary excretion (abst) 373
• 1016290
143207
• . 281144347
• . 917
xliv Subject Index: Vol. 33
particulate guanylate cyclase activity (abst) 266relaxation of mesangial cell (abst) 285release during chronic Na loading (abst) 265renal effects of infusion (abst) 258renin-angiotensin system regulates (abst) 286sequential studies in baboons (abst) 140SIADH (abst) 192
superficial proximal tubule (abst) 289thyroid hormone status (abst) 290type 1 diabetes (abst) 270varying chronic Na intakes (abst) 285vasoconstriction in hydronephrotic (abst) 273vasporessin and renal nerves (abst) 26622Na uptake 291ligand, BP (abst) 271
Atriopeptin IllcGMP, renin (abst) 267hemodynamics and natriuresis (abst) 284
Autoantibodyanti-granulocyte cytoplasmic (abst) 329crescentic GN (abst) 313germline V gene utilization (abst) 325
Autoantigen GP600, HN (abst) 160Automated CAVED (abst) 223Autoradiography, calcitonin (abst) 138
Avidin A, proteinuria (abst) 313Axonal conduction, neuron disease (abst) 625Azotemia
anemic, hematocrit (abst) 184dehydration, urea (abst) 391endotoxin-injected conventional rats (abst) 375high flux dialysis, rHuEPO (abst) 239vitamin B6 deficiency (abst) 388
B cell function in uremics (abst) 185B-endorphin in HD (abst) 221Bacteriuria and diaphragm use (abst) 132Band 3 anion exchanger (abst) 168Barium, K transport (abst) 420Baroreflex sensitivity and sex (abst) 411Bartter' s syndrome
hyperaldosteronism and nephrocalcinosis (abst) 146Basal membranes
structural heterogeneity, IMCD (abst) 432Basolateral membrane
ATP, ADP and AMP inhibition of cation channel(abst) 428
cellular heterogeneity (abst) 430dopamine receptors (abst) 433identification of C1HC03 in IC (abst) 408K channels (abst) 424measurement of potential (abst) 420vesicles, ionic mechanism of Na HCO3 (abst) 407
Bence Jones proteinuriaplasma exchange in ARF due to multiple myeloma. . . 1175
Benzoate, Gln ammoniagenesis (abst) 392Benzodiazepines, transport (abst) 431Beta
blockade, hypertension (abst)carboline and salt, BP (abst)endorphin, reabsorption (abst)receptor, cAMP (abst)subunit of renal Na-K ATPase (abst)
Beta-adrenergicreceptors (abst)stimulation, cAMP (abst)
Beta-l adrenergicantagonist, dialysis (abst) 182
Beta-2-microglobulinallograft inflammatory cells (abst) 442amyloid deposits, chronic HD (abst) 242before and after HD (abst) 760circulating form in dialysis (abst) 332early detection of renal damage in children (abst) 137hemodialysis associated amyloid protein 24:S-30high flux HD (abst) 234in hemodialysis (abst) 755pitfalls in interpretation of changes, HD (abst) 225removal during dialysis (abst) 217skeletal lesions, amyloidosis (abst) 756synthesis in dialysis (abst) 228
Betaine synthesis, TM (abst) 433Bicarbonate
absorption by peptide hormones (abst) 400All, early proximal acidification (abst) 398electroneutral secretion, Cl transport (abst) 403flow rate determines reabsorption (abst) 404kinetics during biofiltration 24:S-120pKa in evaluating dialysate (abst) 623PTH analog inhibits action on HCO3 (abst) 341reabsorption in chronic metabolic acidosis (abst) 404reabsorption to feeding and NaHCO1 gavage (abst). . . . 404regulation of pH in PCT (abst) 403secretion (abst) 402transport in CT (abst) 387
Binding sites for PTH (abst) 338Biocompatibility
granulocyte adherence changes 24:S-68Biofiltration
uremia 24:S-14lBiopsy
anemia a risk factor in (abst) 202comparison in allograft recipients (abst) 440in children (abst) 142
steroid pattern (abst) 207Bladder
osmotic H20 permeability, membrane fluidity (abst) . . . 164Blood
adenosine on renal function (abst) 276autoregulation of flow and GFR (abst) 414azotemic anemic patients, hematocrit 184cooling during dialysis (abst) 221erythropoiesis and erythropoietin levels (abst) 372flow dynamic and UF kinetics in CAVH (abst) 236ionized Ca on systemic arterial pressure (abst) 295membrane interaction in HD (abst) 216mononuclear cells, immunoglobulin production
(abst)mononuclear cells, verapamil (abst)recirculation and effective clearances (abst)release of eicosanoids, dialyzer membranesrheology in IgA nephropathy (abst)transfusions in transplants critical (abst)uremic factor in ATPase (abst)uremic plasma on RBC insulin receptorvasa recta flow in ARF (abst)
297308275258156
318455219
24:S-82134455222378369191volume difference in hematuria (abst)
Blood pressureACE and Ca inhibitors, renal injury (abst) 129
276 and vasopressin changes in hypertension (abst) 294172 extracellular Ca2 modulates Vmc (abst) 304
Subject Index: Vol. 33 xlv
indirect ambulatory monitoring, hypertension (abst) . . . 308instruments for clinical research evaluated (abst) 145K depletion causes Na retention (abst) 299macronutrients (abst) 309nonvasorelaxant atrial peptide ligand (abst) 271portprandial changes during RD (abst) 238PTH level, in humans (abst) 308renorenal reflexes in SHR (abst) 299stress salt (abst) 308
Body mass index, excretion (abst) 383Bombesin, AYP action (abst) 282Bone
Al load and histological disease, HF and HD . . . . 24:S-168desferrioxamine, PTH (abst) 221disease in children on CAPD or CCPD 975disease in dialysis patients (abst) 337extrarenal complications of NS 1184forearm bone mineral content in dialysis (abst) 349formation rate in uremia (abst) 628lead in dialysis patients 601mineral content in transplanted patients (abst) 756preventing disease, CaCo3 and vitamin D3 24:S-178RAS oncogene transformed NIH3T3 cells (abst) 349remodeling, WR-2721 934turnover and 1 ,25-dihydroxycholecalciferol, K
binders 989Bowel pathology, CAPD peritonitis (abst) 133Bradykinin
EGF, cell proliferation (abst) 168hydronephrotic kidney sensitivity to 71PGE2 synthesis and Ca2 in arterioles (abst) 261
Brainmaturation in chilren with NS (abst) 182sex difference in Na transport (abst) 191
Branched-chain amino acidshemodynamics 91
Brush borderarginyl and histidyl groups, anion exchange (abst) 438fluorescence studies, gentamicin (abst) 360Na!H exchange in BBMV (abst) 430phosphonoformic acid binding protein from (abst) 160purification of protein from (abst) 398trypsin (abst) 408
Bubble cell (abst) 198Bumetanide
alkalosis impairs response to (abst) 200Butanol permeability, ADH (abst) 434
Caffeine, papillary damage (abst)Calcitonin
receptors (abst)release during HD inappropriate (abst)..salmon in human (abst)
Calcitiiolbioavailability (abst)clearance in ARFdeficiency in CRFhyperparathyroidism in CRF (abst)plasma kinetics, serum PTH (abst)status changes in hypertension (abst) .synthesis decreased in SHR (abst)women with osteoporosis (abst)
Calciumabsorption by amiloride (abst)absorption, Ca-ATPase (abst)absorption, thiazides stimulate
absorption, verapamil (abst) 343age-associated reduction in cytosolic (abst) 338alkalosis (abst) 338and K channels, cultured mesangial cells (abst) 164anoxia (abst) 359antagonists and CsA (abst) 454AVP sensitive cAMP metabolism by (abst) 268blood ionized, systemic arterial pressure (abst) 295calcitriol deficiency in CRF 722cAMP as second messengers for vasopressin (abst). . . . 286cAMP effect on Na transport (abst) 422carbonate, phosphate binder 24:S-l84cerebrospinal fluid, CSF Ca2 (abst) 297channel blockade (abst) 298channel blockade, PAF (abst) 413channel blockers, capillary pressure (abst) 370channels in basolateral membranes of PTC (abst) 171
chlorothiazide, furosemide, bumetanide (abst) 339chlorthalidone promotes mineral retention,
hypercalciuria 1140compartmentation during anoxia (abst) 361CsA uptake inhibited (abst) 451CsA on signalling and PGE production (abst) 361cytoplasmic inhibitor (abst) 622cytosolic free, diet and changes in medium (abst) 350cytosolic response to vasopressin in LLC-PK1
(abst) 289cytosolic, parathyroid cells, vitamin D3 850cytosolic, vitamin D3 (abst) 349dependency of hypotonic volume regulation (abst) . . . . 436dietary vs. supplemental, BP (abst) 302effects on Na flux (abst) 421epinephrine, PGE2 in MCT; Ni and AVP production
(abst) 287extracellular modulates Vmc (abst) 304fibroblast 4SCa washout (abst) 303free cytosolic in platelets (abst) 300free cytosolic, kidney growth (abst) 391free cytosolic, lymphocytes of SHR (abst) 292FURA 2 measuring (abst) 166hormones affection excretion (abst) 140
hypertension (abst) 300impaired efflux in SHR (abst) 300increases Na transport (abst) 423K and vitamin D in essential hypertension (abst) 627measurement of ionized (abst) 351
messenger system activation, PTH (abst) 340metabolic acidosis (abst) 351Mg flux and NaC1 (abst) 348mobilization by protein kinase C (abst) 277
138 overload differs from cell injury (abst) 359232 oxalate crystal binding in PCT (abst) 170350 oxalate effect on mitochondria (abst) 174
250oxytocin receptors in LLC-PKI cells (abst) 173
530 PGE induced elevation in MDCK cells (abst) 148
722 platelet cytosolic in essential hypertension (abst) 303
755 PTH-independent Pi uptake (abst) 348PTH, vitamin D3 in CRF 1049
294 set point, Al, dialysis (abst) 231
304 uptake by microsomes, maleate (abst) 165
345 urinary inhibitors modulated by 1005vitamin D, SHR (abst) 291
341 vitamin D3 in hypercalciuria (abst) 336347 vitamin D3, SHR (abst) 305
voltage sensitive channels (abst) 158
135
954
xlvi Subject Index: Vol. 33
voltage-gated currents in adrenal cells (abst) 29128K binding protein, localization (abst) 335
Calcium citratephosphate-binding agent for treatment of CRF 95
cAMPacetate (abst) 219apical membrane amplification (abst) 427beta-adrenergic stimulation (abst) 172beta-receptor mediated regulation (abst) 258catabolism, diabetes insipidus (abst) 264Ca2 signaling systems in UMR-106 cells (abst) 271demeclocycline, vasopressin (abst) 252independent of prostacyclin production (abst) 271pertussis toxin, somatostatin inhibition 536pH, and cell to cell communication (abst) 164regulates Cl conductance (abst) 421
Cancernephrocalcin in urine (abst) 209
Candida peritonitis, tuftsin (abst) 244CAPD
aceptic peritonitis (abst) 142bioavailability of calcitriol (abst) 250bone disease in children on, CCPD 975compared to HD 24:S-l23cortisol and corticosteroid binding (abst) 251
diabetic, intraperitonal insulin (abst) 246effluent, immunologic assessment (abst) 244exit site infections, catheter manipulation (abst) 243gram negative infections (abst) 249imipenem in treatment of (abst) 759long term effects, carbohydrate and lipid (abst) 1036long term experience with diabetes (abst) 251
lympho-monokine abnormalities (abst) 627"0" set (abst) 245
pediatric, lipoproteins in (abst) 248performed by relatives (abst) 759peritoneal transport of proteins, dextrans (abst) 1038
peritonitis (abst) 133peritonitis assiciated with bowel (abst) 133peritonitis in HIV infected (abst) 245peritonitis, IP vancomycin therapy (abst) 136
plasticizers exposure, membrane (abst) 246progressive decrease of serum albumin (abst) 757
teaching hospital experience (abst) 142
trimethoprim sulfamethoxazole prophylaxis (abst) 244ultrafiltration lower in children (abst) 247vancomycin superior to cefazolin in peritonitis
(abst) 245
Captoprildiltiazem in adriamycin nephropathy (abst) 382hypertension, renal arter stenosis, RDS (abst) 292iloprost and OKY 046, renal failure (abst) 281in normal subjects (abst) 282measurement of renin in hypertension (abst) 261NaCl reverses renal failure (abst) 364PG blockade in denervated kidneys (abst) 277
post-transplant hypertension (abst) 441renal plasma flow predicts response in HT (abst) 294reversible renal failure (abst) 254test for renovascular hypertension (abst) 296
Carbachol, phosphoinoside (abst) 165Carbicarb in acidosis (abst) 407Carbohydrate, proteinuria (abst) 326Carbonic anydrase staining, new (abst) 399
CardiacANP role, anti-ANP antibody (abst)choice of ESRD treatment according to status
253
of 24:S-l91compliance in myocardial interstitial fibrosis,
uremia 804CsA effect on relaxation of artery (abst) 274
Cardiopulmonary arrest, acid-base (abst) 185Cardiovascular
changes during sleep, ESRD (abst) 628Carnitine
levels, esters in CRF (abst) 213Castration prolongs life, CRF (abst) 373Catecholamine
receptor binding in kidney, aging 1073Catheter
compare 2 in peritoneal dialysis (abst) 250exit site infections in CAPD (abst) 243internal jugular (abst) 218silicone, Dacron cuff (abst) 231subclavian, long-term dialysis (abst) 231tunnel infections reduced (abst) 245
CationATP, ADP and AMP inhibiton in BLM (abst) 428organic transport (abst) 436
CAVHblood flow dynamic and UF kinetics (abst) 236hemodynamics in (abst) 229in vitro simulation and math model 685postdilution vs. predilution (abst) 228report of 100 patients (abst) 757
CAVHDautomated (abst)effecient renal replacement therapy (abst)treatment for newborns with ARF (abst) .
CCK-8, cation transport (abst)cDNA ACE isolation (abst)CD4+ specific suppressor cell (abst)Cell
223233226138150443
ADH regulates volume (abst) 427anatomy of renin-secreting, APKD 1084bubble (abst) 198division, organelle inheritance (abst) 149EGF stimulates mitogenesis in medullary (abst) 255electrophysiological identification of, in CCT (abst).. .. 397epithelial, mesangial and endothelial lines 677functional heterogeneity in CCT (abst) 430isolation of principal and intercalated (abst) 155PHi determination in proximal tubular (abst) 163red production, anemia of ESRD 983red, serum folate levels in dialysis (abst) 756regulatory volume decrease in CCT (abst) 439rubidium uptake 642suppressor induction and inducer lymphokine (abst). . . 451swelling, propionate (abst) 418T suppressor inducer (abst) 450volume regulation in PT (abst) 428
Central pontine myelinolysis (abst) 204Cephalosporin
antibiotics (abst) 368aminoglycoside toxicity 900corrects phagocytic deficiency in HD (abst) 236, 1035protein binding (abst) 247
Cerebrospinal fluid, ANF (abst) 256
Subject Index: Vol. 33 xlvii
cGMPsecond messenger of adenosine, renin release 798
Channelsingle, PT (abst) 425
Childrenaccelerated growth following growth hormone (abst). . . 190ARC/AIDS and NS (abst) 210bone disease, CAPD or CCPD 975CsA induced remission of NS 729CSA, nephrotoxicity (abst) 214cytomegalovirus pneumonia (abst) 223early detection of renal damage (abst) 1378glomerular adaptation after nephrectomy in infants
(abst) 409growth hormone in uremics 45hearing loss in dialysis (abst) 249HUS favorable outcome (abst) 203hypercalciuria in hematuria (abst) 210IgG subclass depression, NS (abst) 333Jordanian, hypertension (abst) 305overview of pediatric nephrology 1016plasma infusion in HUS (abst) 206renal biopsy (abst) 142renal functional reserve in CRF (abst) 188steroid pattern to biopsy (abst) 207treatment of IgAN (abst) 181urine sediment and ARF (abst) 1041vesicoureteric reflux (abst) 179
ChlorideAll role in glomerulo-tubular balance (abst)base exchange regulates pH1 (abst)bicarbonate exchange regulates pH (abst)cAMP regulates conductance of (abst)channel activation, Ca signalling (abst)channel blocker, transport (abst)conductance defect, dialysis (abst)deplete in chronic metabolic acidosis (abst)depletion in K-Cl depletion alkalosis (abst)during euglycemic insulin antidiuresis (abst)extracellular ion concentration, 1P3, PGE2, Ca
(abst)fetal calf serum stimulates conductance (abst)K channel currents in BLM (abst)modulation of channel blocker effect (abst)reversible Cl dependent K flux (abst)transport in BLMV (abst)transport, electroneutral HCO3 secretion (abst)voltage dependant channel (abst)
Chlorophenylthio-cyclic AMP (abst)Chlorothiazide and GFR (abst)Chlorthialidone, hypercalciuria 1140Cholecystokinin and VIP (abst) 288
CholestryamineLDL catabolism (abst) 384
resin, PAN (abst) 376Choline dehydrogenase, IM (abst) 433
Chorionic gonadotropin, pregnancy (abst) 260Chronic renal failure
adrenergic receptors (abst) 295alanine flux (abst) 395
alimentary protein, K restriction (abst) 1041ANP (abst) 263atrial peptide SC-44900 effects (abst) 290Blacks on dialysis (abst) 204brain maturation in children (abst) 182
calcitriol (abst) 755calcium citrate 95calorie restriction (abst) 386cation transport in thymocytes (abst) 371
cellular cytokine generation (abst) 234creatinine deficit, toxin production (abst) 375dietary treatment, amino acids, keto acids (abst) 138
drug protein binding 996early, effect of protein (abst) 204enalapril long term (abst) 379fluid intake (abst) 381
growth, enalapril (abst) 374hair and serum Al in children (abst) 139hypermetabolism in remnant kidney (abst) 129infant nutritional management (abst) 193insulin release from pancreatic islets 1066
lisinopril (abst) 142low protein diets (abst) 376lupus nephritis, indices of outcome (abst) 331
nisoldipine (abst) 189oxydative metabolism of granulocytes (abst) 625PAN differences in rat strains 524
pericarditis 24:S-10predictors of progression (abst) 183
progression in solitary kidneys (abst) 206
proteolysis by thyroid hormone (abst) 391
pruritus (abst) 759
psychological symptoms 24:S-l8PTH and fatty acids oxidation in skeletal muscle 555PTH and vitamin D3 1049
rational therapeutic principles 116renal functional reserve in children (abst) 188
response to hANP (abst) 287
secondary hyperparathyroidism, hemodialysis 1041TCA cycle (abst) 624thromboxane synthetase antagonist ameliorates 77thyroid hormone (abst) 195
urinary abnormalities (abst) 37524-hour integrated GH determinations in children
(abst) 197Chronic renal insufficiency
carnitine levels and esters (abst) 213hyperparathyroidism in hormonal disorders (abst) 133
protein stimulation (abst) 103324,25(OH)2D3 blunts hypercalcemic effect (abst) 347
Chronic serum sickness, PGS (abst) 1037Cirrhosis
ANP infusion (abst) 257ANP role in head out water immersion (abst) 272eicosanoids in control of hemodynamics (abst) 272
primary biliary, CSA (abst) 212Clathrin coated vesicle proton pump
structure (abst) 177
17 kDa (abst) 174Clinical competence in nephrologists 608Clone
early growth response gene (abst) 175
MDCK cells with electrical resistance (abst) 406Na dependent sugar transport system (abst) 438molecular, of gene (abst) 155
sequencing of cDNA (abst) 159Cobalt
action, antidiuretic hormone (abst) 260myocardium and skeleton (abst) 152
Coccidioidomycosis, amphotericin B(abst) 193
421399403421162416379409402271
163168428422429417403422255412
xlviii Subject Index: Vol. 33
Coichicine, gentamicin in uptake (abst) 176Collagen
gel tissue culture, TIN (abst) 137trimeric type I (abst) 158
Complementactivated C3 and C5, pulmonary artery (abst) 233activation in plasma exchange (abst) 756activation, membrane proteins (abst) 323activation, polymorphonuclear leukocyte, HD (abst)... 225binding of, to membranes (abst) 218C5b-9, membranous nephropathy (abst) 331decay accelerating factor (abst) 324depletion, immune complex GN (abst) 323membrane attack complex (abst) 153streptococcal nephritogenic antigen effect (abst) 144
Conductancevesicles deliver water particles (abst) 261
Conductivity, sodium taurocholate 782Contrast dye and HD (abst) 229Contrast media-induced ARF 699Contrast nephropathy
azotemic diabetics (abst) 201in NS (abst) 180
Contrast nephrotoxicity (abst) 208Contrasuppression, aTBM (abst) 319Converting enzyme inhibition
All blockade (abst) 384protein restriction, glomerular injury (abst) 386puromycin aminonucleoside nephrosis (abst) 373
Coronary arterybypass, ESRD (abst) 225disease in allograft recipients (abst) 136
Cortical collecting ductmetabolic acidosis (abst) 406
Cortical collecting tubuledifferentiated transport functions (abst) 167electrophysiological ID of cells (abst) 397K adaptation (abst) 418volume regulatory increase (abst) 436
Cortical interstitial cellsensitivity of hydronephrotic kidney to bradykinin 71
Cotransport, glutamate/H (abst) 394Crack abuse in renal disease (abst) 181Creatininase activity in CRF (abst) 375Creatinine
fingernail (abst) 181CrEDTA/TcMDP ratio (abst) 139
Crescentic glomerulonephritisanti-granulocyte cytoplasmic autoantibody (abst) .. . 313, 329GBM necrosis and crescent organization 966
Crioglobulinemiaglomerular immune deposits in (abst) 626
Crystalscalcium oxalate in PCT (abst) 170
Culture of glomerular cells 677
Cuprophanef32M (abst) 220
Cyclooxygenasebiocompatibility of HD membranes (abst) 217inhibition (abst) 277
Cyclophosphamideprednisone, in membranous glomerulonephritis (abst) . .. 185
CyclosporineANF in nephrotoxicity (abst) 356associated chronic nephropathy (abst) 366
Ca channel blocker inhibition (abst) 451dietary protein intake affects (abst) 357dietary protein restriction, rejection (abst) 1038effect on hemodynamics (abst) 368elevated metabolites (abst) 446erythromycin (abst) 448fractional excretion of Na (abst) 451genetic susceptibility to hypertension (abst) 293ginkgolide mixture protects vs. toxicity (abst) 449glomerular lesions analyzed (abst) 448hyperchloremia, hyperkalemia (abst) 361hypotonic cell volume regulation by (abst) 368infusion rate on nephrotoxicity (abst) 442interacts with Ca antagonists (abst) 454long term course of chronic nephropathy 590low dose (abst) 445MCNS, T cell abnormality (abst) 329methylprednisolone pharmacokinetics (abst) 454nephroxicity in Sprague-Dawley (abst) 443nifedipine, propanolol (abst) 367NS in children (abst) 185on Ca signalling and PGE production (abst) 361oral bioavailability after transplant (abst) 455pediatric transplantation (abst) 445polyglobulism (abst) 452post-transplant glucose intolerance (abst) 450primary bilaiary cirrhosis (abst) 212reduces degranulation of PMN-leukocytes (abst) 455renin content, concentration in hypertension (abst).... 267single kidney and injury from (abst) 443suppressor cell induction, inducer lymphokine (abst) . . . . 451toxicity, Ca and protease restriction (abst) 359tubular function (abst) 444TxB2 (abst) 254urinary Mg wasting (abst) 451vasoconstrictor effects of norepinephrine (abst) 442verapamil interaction (abst) 449verapamil on PGE production (abst) 355vs. donor specific transfusion (abst) 444
Cyclosporine Adevelopment of immune-mediated interstitial
nephritis 1113focal GS (abst) 322heart transplant, acidification study (abst) 440hydergine (abst) 1037hyperreninemic hypoaldosteronism (abst) 274idiopathic nephrotic syndrome (abst) 1035
IgA nephropathy (abst) 131
relaxation of artery (abst) 274remission of relapsing NS in children 729renin secretion (abst) 446renin secretion in isolated JG cells 947rheumatoid arthritis (abst) 761T cell activation pathway (abst) 453
CystAPKD histochemical studies (abst) 333
cystic kidneys 610MDCK, enlargement in hydrated collagen gel (abst) ... 386reducing volume in APKD (abst) 181
screening protocol for ADPKD (abst) 191tubular origin function changes in cystic disease 8
Cystic diseasediphenylthiazole 1130
Cystic fibrosismicronephrocalcinosis (abst) 435
Subject Index: Vol. 33 xlix
Cystinuria, thiola therapy (abst) 758Cytochrome P-450 expression (abst) 162
Cytokine generation, CRF (abst) 234
Cytomegalovirusin grafts (abst) 444pneumonia, HD (abst) 223
Cytoplasmic alkalinization, GF (abst) 266Cytotoxic antibodies
HLA B + DR graft matching (abst) 133
Cytotoxins, TNF (abst) 320
Cytoxan, lupus nephritis (abst) 179C3 levels, SLE renal activity (abst) 328C3/C5 convertases, anti-FX1A (abst) 321
D-glucitol and aldose reductase role 635Dahl rat, hypertension and renal disease 1119Data base for tracking HD patients (abst) 220Decay accelerating factor (abst) 324Deferoxamine
ARF (abst) 363
mucormycosis, dialysis (abst) 238Dehydration
and azotemia (abst) 391
hypertension (abst) 307vasopressin and blood changes (abst) 141
Deoxyribonucleic acid, lupus nephritis 487Desferrioxamine
infusion test (abst) 625PTH response to Ca change in bone disease (abst) .... 345
Desmin, marker for mesangial cell (abst) 158Dexamethasone
coichicine, CPM (abst) 204heparin sulfate (abst) 161
Diabetesarachidonic acid (abst) 393azotemic, contrast nephropathy (abst) 201CAPD, intraperitoneal insulin (abst) 246
cold hemodialysis (abst) 222decrease in Na-K ATPase activity (abst) 420determination of urine albumin excretion (abst) 214enalapril, GFR and RPF (abst) 189ESRD, racial disparity in survival (abst) 187fish oil (abst) 385genetic linkage, DNA marker (abst) 1035GFR, fluid volume and ANF (abst) 268glycation of albumin 673growth factor in nephropathy (abst) 201hyperfiltrating, PGE2, GFR and albumin (abst) 199hypernatremia in women (abst) 179hypertension alters PG response to (abst) 378hypouricemia (abst) 208improved prognosis for transplantation (abst) 441intracellular Na, role of glucose 792intralysosomal proteolytic enzymes, hypertrophy
(abst) 376long term experience in CAPD (abst) 251PAH (abst) 389PGE2 production in hypertension 1100
plasma clearances (abst) 187
protein kinase during renal growth (abst) 393
proteinuria determines prognosis (abst) 197
risks of nephropthy (abst) 193role of myo-inositol (abst) 372
tubuloglomerular feedback (abst) 412
Diabetes insipidusabnormal cAMP catabolism (abst) 264
catabolism of cAMP and cGMP (abst) 267factor VIlIc, MAP, pulse and renin in (abst) 182platelet AVP as marker (abst) 180
Diabetes mellitusalpha-hAMP hemodynamics (abst) 282ANP related to blood glucose (abst) 759
carbohydrate and proteinuria (abst) 326disordered Ang II receptor regulation (abst) 302
glomerular size and charge selectivity 100
hemodynamics in childhood, insulin-dependent (abst) ... 757
microalbuminuria and GFR (abst) 189poorly controlled ANF (abst) 254role of All receptors (abst) 380
Diabetes, type 1atrial natriuretic peptide (abst) 270
Diabeticreversal of hyperfiltration (abst) 387
Diabetic nephropathyacetazolamide (abst) 209body fluid volumes, osmotic gradient (abst) 194protein and BP (abst) 190
protein restriction, lipoprotein (abst) 213renal reserve, protein restriction (abst) 184
DialysateCAVJ4D efficient (abst) 233peritoneal, volume measurements 64pKa influence in bicarbonate (abst) 623
Dialysisacetate and succinate (abst) 228acid-base status 24:S-l 17acinetobacter peritonitis (abst) 246
adequacy 24:S-92Al and Fe overload in chronic dialysis 24:S-163ARF requiring (abst) 756associated subclavian vein stenosis 1156asymptomatic patients, amyloidosis (abst) 236beta-adrenergic antagonists (abst) 182bicarbonate kinetics during biofiltration 24:S-120bone disease (abst) 337bone disease in children on CAPD or CCPD 975bone lead 601CAPD performed by relatives (abst) 759chloride conductance defect (abst) 379circulating form of /32M (abst) 332complement activation, membrane compatibility
(abst) 230computerization of REDY sorbent (abst) 238CPR attitudes (abst) 224daily, long-term clinical metabolism 24:S-137DFO test (abst) 625drainage bag size, transport 248endotoxin-like interleukin- 1 inducing activity 29ESRD choice of treatment according to cardiac
status 24:S-191familial risk of CRF in Blacks (abst) 204first use reactions 24:S-37forearm bone mineral content (abst) 349four different short techniques (abst) 236growth hormone in uremia 45hearing loss in children (abst) 249
herpes zoster (abst) 227
high flux membranes, /32M (abst) 217
high flux, azotemia and survival (abst) 239
high flux, polysulfone membrane (abst) 239HLA-antibodies removed (abst) 443
1 Subject Index: Vol. 33
hypercalcemic, PTH and bone Al levels (abst) 345hypersensitivity (abst) 224hypertonic hemodiafiltration 24:S-132indium-ill-leukocyte scan (abst) 223induced hypoxemia 24:S-57infant nutrition management (abst) 193
integrated approach to ESRD management 24:S-145intermittent ambulatory peritoneal (abst) 244intradialytic bicarbonate infusion (abst) 227long term effect of CAPD on carbohydrate, lipid
(abst) 1036low K bath (abst) 225lupus nephritis and ESRD (abst) 140membranes, lipoxygenase activity (abst) 240morbidity (abst) 625morbidity during short term (abst) 237National Cooperative Dialysis Study (abst) 227of the future 24:S-lOOpericarditis 24:S-10peritoneal catheter tunnel infections (abst) 245peritoneal transport of water, solutes and proteins
(abst) 1036phosphatidylcholine in peritoneal (abst) 247polyacrylonitrile vs. cuprammonium rayon (abst) 234polyelectrolytes as osmotic agents for 925polymorph superoxide production (abst) 248pruritus, iron deficiency (abst) 226quality of life in aged (abst) 758recirculation and effective clearances (abst) 219red cell and serum in (abst) 756Redy system (abst) 220related amyloidosis 24:S-32removal of phosphate in uremics 24:S-180renal failure, solute specific (abst) 250renal recovery and survival in ARF (abst) 238serum aluminum monitoring (abst) 218short, rapid blood flow (abst) 237somatic and psycosocial indicators (abst) 758
sorbent, Redy compute (abst) 234subclavian catheter (abst) 231
survival analysis (abst) 188survival long term (abst) 249synthesis of 2M (abst) 228TACurea and treatment schedules 24:S-105teaching hospital experience (abst) 142termination a cause of death (abst) 235transcutaneous gas monitoring (abst) 215volume and lymphatic flow in peritoneal (abst) 247water treatment (abst) 223
Wegener's granulomatosis recurs 1035Dialyzer
cuprophane, f32M (abst)cuprophane and polyacrylonitrile performancedifferent membranes, granulocyte elastasefistula recirculation (abst)high efficiency, shortens HD time (abst)high flux, specific features (abst)membrane and HD on pulmonary mechanics (abst).membranes, syndromes associated with use"0" set in CAPD (abst)on line sterile rinse of high flux (abst)release of eicosanoids from blood cellsurea and creatinine clearances (abst)
Diaphragm use and bacteriuria (abst)
Dietacute effects of meat meal on hemodynamics (abst). . . 1033age and sex, response to immune injury 561animal protein rich, kidney stone (abst) 335calorie restriction in CRF (abst) 386Ca2 in SHR (abst) 291cytosolic free Ca concentration (abst) 350different sources of protein in humans (abst) 411HD amino, keto acid levels (abst) 143intake pattern and glomerulosclerosis (abst) 385low protein, declining renal function (abst) 139PAN, proteinuria and early sclerosis (abst) 378phosphorus deprivation (abst) 337progression of early CRF (abst) 204renal response to acute protein meal (abst) 386sodium, aromatic L-amino acid decarboxylase (abst) . . 252zinc deficiency and uremia 1091
Digitalisnatriutetic factor (abst) 192receptor, stress (abst) 304
Digoxinlike material, hypertension (abst) 307
Diltiazemtransplant, CsA (abst) 446
Diphenylthiazole, cystic disease 1130Distal nephron
trichlormethiazide (abst) 426Distal tubule, ionized Ca (abst) 351Diuresis
ANF analog, plasma, cGMP levels (abst) 176osmotic, ADH inhibition (abst) 432urinary magnesium excretion (abst) 141
Diureticchlorothiazide, furosemide and bumetanide (abst) 339loop, nephrotoxic ARF (abst) 364microalbumin excretion in diabetics (abst) 192NMR imaging (abst) 435tubular site of action of (abst) 10363H-matolazone binding (abst) 415
Djenkolic acid, ARF (abst) 359DNA
glomerular deposits (abst) 316immunoadsoprtion column for removal (abst) 199linked marker for APKD (abst) 184polymerase activity, ARF (abst) 623synthesis in mesangial cell (abst) 149synthesis, thrombin (abst) 172
DOCAsalt treatment on urinary prostaglandins 930
Donationrenal reserve filtration capacity (abst) 1033
Donoradult kidney in juvenile (abst)
Dopamineexcretion, volume expansion, natriuresis (abst) .failure to induce natriuresis (abst).receptors on BLMV (abst)
Dopamine-l in hypertension (abst)..Dopaminergic stimuli on AVP (abst)Doxazosin and hemodynamics (abst)Drug protein binding, CRF
Edema, extrarenal complications, RF 1184Effusions due to decapsulation (abst) 199EGF, mitogenesis in cells (abst) 255
22024:S-5524: S-90
241235226220
24: S-49245241
24: S-82219132
757
415410433306283144996
Subject Index: Vol. 33 h
Eicosanoidcontrol of hemodynamics in cirrhosis (abst) 272production by goldfish kidney (abst) 273production, angiotensin II (abst) 257synthesis, anionic sites neutralized (abst) 282
Eicosapentaenoic acid diet, GN (abst) 285Elastase mediates injury (abst) 312Electrical property of GEC (abst) 172Electrolyte
catecholamine receptor binding 1073composition of tubular cells in gentamicin
nephrotoxicity 1107hyponatremia (abst) 186
Electrophoresisanalysis of efferent arteriole serum protein 1181
Electrophysiology of PT cells 508Enalapril
ACE inhibitor in diabetic nephropathy (abst) 178BP control, weight change in HD (abst) 299CRF (abst) 379diabetes, GFR and RPF (abst) 189growth, CRF (abst) 374HCTZ in genetically hypertensive dogs (abst) 293microalbuninuria (abst) 209Na and H20 balance in low sodium diet (abst) 292natriuresis of ANP (abst) 1038non-invasive measurement of hemodynamics of
(abst) 301protein restriction reduces albuminuria (abst) 377
End-stage renal diseaseacid-base status (abst) 246acute pancreatitis diagnosis (abst) 183ANP in 70 patients (abst) 287coronary artery bypass grafting (abst) 225current perception threshold, nerve conduction
(abst) 241daily dialysis 24:S-137dialysis related amyloidosis 24:S-32diphenylthiazole and ADPKD 1130erythropoietin (abst) 152glistening speckled appearance (abst) 197hematopoietic progenitor cell response 983heparin compared in HD and HF 890HIV staging system (abst) 242idiopathic membranous nephropathy, untreated
patients 708integrated approach to management 24:S-145intradialytic bicarbonate infusion (abst) 227lipids in diabetic and nondiabetic (abst) 216racial disparity, survival in diabetic (abst) 187
survival patterns in lupus nephritis (abst) 212teatment strategy according to cardiac status 24:S-191termination of dialysis as cause of death (abst) 235
End-stage renal failureCanadian public health (abst) 205cardiovascular changes during sleep (abst) 628comparison of membranes 24:S-44
EndocytosisNa solute cotransport (abst) 161
Endorphin, beta, reabsorption (abst) 275Endosome
Cl dependent H ATPase (abst) 159Endostreptosin in GN (abst) 180Endothelial cell
Endotoxemiabacteremia and urosepsis (abst) 212
Endotoxinazotemia and nephropathology (abst) 375myristyl acylation, IL-l precursor (abst) 151PGE2 stimulation, pertussis toxin (abst) 289
Enzymeactivity revealed by carbonic anhydrase staining
(abst) 399BBM glucose transport (abst) 431
Eocosanoidsmesangial cell injury (abst) 286
Eosinophil, allograft dysfunction (abst) 453Eosinophilia
in HD membrane related 24:S-73heparin sensitivity 24:S-84
Epidermal growth factorcAMP and vasopressin conductivity (abst) 255cytoplasmic alkalinization (abst) 266glucose-6-phosphate dehydrogenase (abst) 173hypertrophy (abst) 387PGE2 production (abst) 274
Epithelial barrier, phosphate transfer 58Epithelial cell
anti-FX1A inhibits decay of C3/C5 convertases(abst) 321
glomerular, antibodies (abst) 314glomerular visceral, heparin (abst) 309interleukin I (abst) 317
Epithelial growth factorbradykinin in proximal tubule cells (abst) 168
Epithelial polarity, ischemia (abst) 367Erythrocyte ferritin, HD (abst) 626Erythrocytes
C3b receptor in SLE (abst) 760Erythromycin
CsA simultaneously (abst) 448Erythropoiesis
deferoxamine, Al (abst) 215rHuEPO in transplant recipients (abst) 452
Erythropoietincardiac performance in HD patients (abst) 628chronic HD (abst) 218hypertensive effect (abst) 207mechanism of action (abst) 152pharmacokinetics of rHuEpo in HD (abst) 262recombinant, HD (abst) 232
Escherichia coliresistance (abst) 131
scarring (abst) 325
Essential hypertension, hemodynamics 875Ethylene oxide in HD 24:S-62Etylendioxid IgE antibodies (abst) 755Excretion
altered hemodynamics on albumin (abst) 434ammonium, proximal tubular acidosis (abst) 183extrarenal complications of nephrotic syndrome 1184magnesium, control mechanisms (abst) 140mild charge modification of albumin (abst) 433, 1039urinary angiotensin, marker of renal production
(abst) 1036urinary divalent cation, hypertension (abst) 29724-hour protein (abst) 142
Exerciseamplification by, signal of immune complexes (abst). . . 314 tolerance in HD patients (abst) 200
lii Subject Index: Vol. 33
Exogenous adenine nucleotides (abst) 355Extracapillary glomerulonephritis
factors determining outcome (abst) 1035
Fabry's disease (abst) 182Fanconi syndrome
15N glutamine metabolism (abst) 393Fatigue, HD (abst) 239Fatty acid
CRF, PTH and oxidation in skeletal muscle 555isovolumetric regulation of S2 (abst) 438macrophage chemotaxis (abst) 323omega-3 polyunsaturated (abst) 456peroxidation of polyunsaturated (abst) 624transport by BLMV (abst) 439
Fc receptor, IgG (abst) 322Fibrin
tissue factor synthesis, LPS, TNFa (abst) 327type 1 plasminogen activator inhibitor (abst) 330
FibroblastNa/H antiport, race (abst) 29745Ca washout, race (abst) 303
Fibronectinadhesive glycoproteins in mesangial cells (abst) 154glomerular cells (abst) 318HD effect on concentration (abst) 217
Fibrosismyocardial interstitial, uremia, cardiac compliance. . . . 804nephrotoxic nephritis (abst) 321non-coronary myocardial in uremics (abst) 301
Fingernail creatinine (abst) 181Fish oil
diet, PGE2, All (abst) 384GFR, PG production and serum lipids in diabetes
(abst) 385nephrotoxic serum nephritis (abst) 322
FistulaHD associated subclavian vein stenosis 1156recirculation (abst) 241
Fluiditymembrane asymmetry in MDCK cells (abst) 163
Fluorescence activated cell sort (abst) 155Fluorophore, PT vesicles (abst) 437Flurazepam (abst) 422Fluroescence, H20 permeability (abst) 435Focal glomeruloscierosis
analogy to atherosclerosis 917cyclosporine A (abst) 322during AIDS (abst) 1041treatment of hyperlipidemia reduces injury 667
Focal segmental sclerosisdifferences in PAN in rat chains 524
Free radicalpostischemic injury 843pyelonephritis (abst) 371
Fura, calcium cell permeability (abst) 166Furosemide
D-glucose transport, gentamicin (abst) 363hemodialysis (abst) 1036kinins in renin release (abst) 274oxidative metabolism and Ca2 uptake (abst) 361m-technetium-pertechnetate uptake (abst) 416
Galactose, hemodynamics (abst) 372Gamma glutamyltransferase (abst) 391
Gamma interferonLPS (abst) 316STZ (abst) 312
Gamma-G6 monoclonal antibody 543Gemfribrozil, nephrotic syndrome (abst) 192Gene
albumin transcription in liver of nephrotic rats (abst). . . . 156AVP in regulation in rat (abst) 285calcitonin release during HD (abst) 232Class II MHC expression, TIN (abst) 158cloning (abst) 155
early expression, hypertrophy or phyperplasia(abst) 168
molecular cloning of growth response (abst) 175non- H-2, murine apoferritin, ICGN (abst) 312PC-12 cells (abst) 162transcription by proximal tubule cultures, pH (abst) . . . 169variability of C4 number in nephrotic syndrome
(abst) 165Genetic marker for ADPKD (abst) 625Gentamicin
ARF, ANP protects against (abst) 366colchicine, cortical uptake (abst) 176electrolyte composition of tubular cells 1107fluorescence studies (abst) 360focus of tissue necrosis and ARF 84furosemide enhances D-glucose transport (abst) 363glomerular hemodynamics (abst) 353hypoperfusion ARF (abst) 357nephrotoxicity (abst) 355nephrotoxicity in rat neonates 36phosphatidylinositol cascade (abst) 360phospholipase C (abst) 362thyroid hormone, lysosomal volume (abst) 356x-ray imaging (abst) 355
Germline V, autoantibodies (abst) 325Ginkgolide mixture, CsA toxicity (abst) 449Globulin binding during CAPD (abst) 251Glomerular basement membrane
anti-GBM nephritis, proteinuria reduced by CsA(abst) 1039
hematuria structure (abst) 138immune complexes (abst) 314laminin heterogeneity (abst) 149metalloproteinases (abst) 310necrosis and crescent organization 966streptococcal proteinase (abst) 311
Glomerular diseasehypercholesterolemia 498vimentin filament (abst) 134
Glomerular endothelial cellDNA synthesis (abst) 149surface electrical property (abst) 172
Glomerular epithelial cellsheparan sulfate proteoglycans synthetized by (abst) ... 174membrane attack complex of complement (abst) 153
Glomerular filtration rateACE inhibition (abst) 259ANF in diabetics (abst) 268autoregulation of blood flow and (abst) 414BCAA and hemodynamics 91captopril in control of (abst) 305chlorothiazide (abst) 412contrast media-induced ARF 699handling of 99mTc-DMSA (abst) 1034
Subject Index: Vol. 33 liii
ischemic rate kidneys (abst) 1039protein intake determinant of (abst) 183recovery from partial ureteral obstruction 775theophylline in ischemic ARF 24
Glomeruliisolated for quantitation of immune deposits 89735S labelled proteoglycans (abst) 313
Glomerulonephritisextracapillary, factors determining outcome (abst). . . . 1035helix pomatia agglutinin (abst) 320IgAN, lambda light chain IgAN 584immune complex, antibodies vs. laminin etc (abst) . . . . 317immune complex, apoferritin (abst) 314immune complex, complement depletion (abst) 323immune complex, eicosapentaenoic acid diet (abst). . . . 285immune complex, proteolytic activity (abst) 326immune complex, TxA2 synthetase inhibitor (abst) . . . . 315insulin, growth factor stimulate, TGFbeta (abst) 152intraglomerular monocytes (abst) 130isolation of glomeruli for quantitation of immune
deposits 897lupus, C3 and C4 metabolism (abst) 130mononuclear phagocytes in (abst) 135New Zealand survey (abst) 133patterns associated with hepatitis B (abst) 143platelets mediate neutrophil (abst) 318polyanion neutralization (abst) 414poststreptococcal, endostreptosin testing (abst) 180predictors of outcome (abst) 143pregnancy (abst) 132procoagulant activity augmented (abst) 134procoagulant activity of macrophages (abst) 130prostaglandins production (abst) 264
Glomerulopathies, protein (abst) 200Glomeruloscierosis
cell lines from transgenic mice 677diabetes mellitus 100diet intake pattern (abst) 385hypertrophy, cell injury (abst) 374sex vulnerability (abst) 378
Glomeruluscomparison of MLM and SEM to determine size
(abst) 325fibronectin (abst) 318plasminogen activator activity 868
GlucagonPGE mediate amino-acid induced rise in hemody-
namics 1147Glucocorticoid
metabolic acidosis (abst) 397Na-K ATPase in epithelial cells (abst) 155regulate Na absorption (abst) 416
Gluconeogenic metabolism (abst) 395Glucose
control, aerobics (abst) 326intolerance and hypertension (abst) 296intolerance, hypertension relationship (abst) 298intracellular sodium in PT of diabetic 792metabolism, X-linked hypophosphatemia (abst) 388post-transplantation intolerance (abst) 450
Glutamate H cotransport (abst) 394Glutamine
interaction with glutathione in PT (abst) 390Glutathione
altered content, post-ischemia (abst) 365
free radical-mediated postischemic injury 843hypoxia, depletion of (abst) 363redox ratio, ischemia 812transferase in urine 571
Glycan-phospholipid in MS cells (abst) 175Glycerophosphorylcholine, ADH (abst) 255Glycine protects against injury (abst) 357Glycolytic metabolism (abst) 395Glycoproteins in Heymann nephritis (abst) 164Goldfish eicosanoid production (abst) 273GP 330
Heymann nephritis (abst) 310matrix receptor (abst) 165
Graftcytotoxic antibodies and HLA B-DR matching (abst) .. 133
damaged kidneys in transplantation (abst) 146rejection, T cell immunization (abst) 135vs. host disease, murine (abst) 311
Granulocyteadherence changes, biocompatibility 24:S-68elastase, different dialyzer membranes 24:S-90
Granulocytopenia during HD (abst) 222Growth
ACE inhibitor suppresses growth of cells (abst) 296kidney, free cytosolic Ca2 (abst) 391PDGF, pH and Ca (abst) 156promoting factors after nephron loss (abst) 392renal, protein phosphorylation (abst) 159
Growth factordiabetic nephropathy (abst) 201EGF and platelet derived GF, prostanoid synthesis
(abst) 162epidermal excretion and dietary protein (abst) 376G proteins, thrombin and (abst) 160gene encoding in cisplatin nephrotoxicity (abst) 365human B cell (abst) 448platelet-derived, regulated by thrombin (abst) 148
Growth hormoneaccelerated growth following (abst) 190IGF-l, renal functin after GH injection (abst) 205in children with CRF (abst) 197Na retention (abst) 256phosphate reabsorption (abst) 344uremia 45
Growth inhibitor, crystal (abst) 340Gs alpha mutations (abst) 166GTP-binding proteins of PTH (abst) 344
H-ATPasemetabolic acidosis (abst) 404vanadate (abst) 394
HATPase, cloning and cDNA (abst) 159Habu snake venom, sulindac (abst) 310Hantavirus nephropathy (abst) 356Heart failure
ANF (abst) 262ANF in rats with high output 656ANF prevents sodium retention (abst) 272AVP gene expression in congestive (abst) 270role of renal nerves (abst) 418
Helix pomatia agglutinin (abst) 320Hematocrit
azotemic anemic patients (abst) 184blood viscosity in azotemic patients (abst) 184dietary Ca and Fe interaction, SHR (abst) 302
liv Subject Index: Vol. 33
Hematuriahypercalciuria in childhood (abst) 210neoplasia (abst) 187overview of pediatric nephropathology 1016RBC volume difference (abst) 191
thin membrane nephropathy (abst) 137Hemodiafiltration
AN 69 membrane 24:S-135biofiltration in uremia 24:S-141
Hemodialysisacquired cystic disease, adenocarcinoma (abst) 1040adequacy 24:S-92altered interleukin-1 (abst) 216associated amyloidosis (abst) 231associated subclavian vein stenosis 1156automated CAVHD (abst) 223
B-endophin levels (abst) 221blood cooling, neutrophils (abst) 221blood/membrane interaction (abst) 216bone lead 601/32—microglobulin in group (abst) 755/32M amyloid deposits (abst) 242
132M associated with amyloid protein in HD 24:S-30132M before and after (abst) 760f32M during high flux (abst) 234
capsulo synovial and bone amyloidosis 24:S-35cardiovascular instability 24: s-i 86changes in cardiac performances, rHuEPO (abst) 628
chronic, HIV testing in (abst) 235cold, in diabetics (abst) 222compared to CAPD 24:S-123complement receptors on neutrophils, monocytes
(abst) 222continuous arteriovenous 24:S-159contrast dye (abst) 229correction of anemia (abst) 189, 204correction of coagulation disturbances (abst) 622correction of phagocytic deficiency (abst) 236CPR attitudes (abst) 224cuprophane and polyacrylonitrile performance .... 24:S-55data base system (abst) 220dialyzer urea and creatinine clearances (abst) 219
down-regulation of neutrophils (abst) 241
enalapril, BP and weight change (abst) 299endotoxin-like interleukin- 1, in vitro dialysis 29erythrocyte ferritin (abst) 626erythropoietin treatment, exercise (abst) 200ethylene oxide and hypersensitivity reactions 24:S-62exercise capacity indreases, anemia correction
(abst) 206first use reactions 24:S-37four short dialysis techniques (abst) 236furosemide (abst) 1036GLA protein and bone films (abst) 232
glistening speckled appearance (abst) 197
granulocyte adherence changes 24:S-68heparin effects on plasma GH (abst) 626high flux dialyzers (abst) 226H1V infection transmission (abst) 233HIV infections (abst) 230
interleukin hypothesis 24:S-27interleukin-1 relevance to 24:S-21low molecular weight heparin 890measurement of thermal energy balance (abst) 235
membrane biocompatibility (abst) 217
membranes compared 24:S-44morbidity (abst) 625morbidity during short term (abst) 237muscle high energy metabolites (abst) 240muscle metabolism (abst) 239National Cooperative Dialysis Study (abst) 227neutrophil migration 24:S-86on-line sterile rinse of high flux (abst) 241optimum nutritional treatment, amino, keto levels
(abst) 143
oxalate appearance (abst) 198phagocytic deficiency, cephalosporin (abst) 1035pharmacokinetics of rHuEpo (abst) 262pitfalls in interpretating p2M concentrations (abst) . . . . 225plasma fibronectin (abst) 217
platelet angiotensin II receptors (abst) 230platelet lipoxygenase stimulation 24:S-80plethysmography (abst) 228poison treatment 735polyamide hemofilter (abst) 237polymorphonuclear leukocyte function (abst) 225postprandial BP during (abst) 238PTH and ionized Ca (abst) 337PTH, erythropoietin (abst) 224quality of life, r-EPO (abst) 242r-.HuEPO (abst) 218recombinant erythropoeitin (abst) 232, 240rHuEPO and anemia 623secondary hyperparathyroidism, CRF (abst) 1041
shortened time using high efficiency dialyzer (abst). . . . 235silicone catheter, Dacron cuff (abst) 231somatic and psychosocial indicators in chronic (abst) . . 758successful outcome of pregnancies (abst) 132
technetium-thallium subtraction scanning (abst) 1041technique and survival (abst) 249thymosin, anti-influenza antibody (abst) 208tumor necrosis factor, 11-1 (abst) 229urea kinetic modelling (abst) 216urea kinetics (abst) 239
Hemodynamicsacute effects of meat meal (abst) 1033All and PGI (abst) 413alpha-hANP in diabetes mellitus (abst) 282and amino acids 91anemia treatment (abst) 232antibody induced mesangial cell lysis (abst) 327atriopeptin III (abst) 284Ca channel blockade vs. Ca variation (abst) 298captopril and CyA in diabetes (abst) 193
captopril in normal patients (abst) 282
catecholamine receptor binding in kidney 1073
CAVH (abst) 229
central alpha 2 receptor (abst) 298
cyclosporine (abst) 368efferent arteriole serum protein, electrophoresis 1181
galactose (abst) 372
gentamicin (abst) 353glucagon and prostaglandins mediate amino acid rise
in 1147insulin-dependent diabetes mellitus (abst) 757irradiation of ureteral obstruction (abst) 358math model of tubuloglomerular feedback (abst) 412natriuresis of essential hypertension 875non-invasive measurement of enalapril (abst) 301
nonsteroidal antiinflammatory drugs (abst) 178
Subject Index: Vol. 33 lv
PAN and proteinuria (abst) 410paradoxical effects of insulin (abst) 410passive Heymann nephritis, C5A (abst) 755prednisolone increases glomerular permeability 1169pylonephritic renal scarring (abst) 195theophylline prevents hypoxemia-induced changes ... 1078vasopressin and oxytocin binding sites 959
HemofiltrationAl load and histological bone disease 24:S-168AN69S membrane 24:S-150in vitro simulation and math model 685low molecular weight hepann 890postdilution vs. predilution in CAVH (abst) 228protein loss during 24:S-114pump assisted, acute uremia 24:S-154ultrafiltration-pump assisted 24:S-157
Hemolytic uremic syndromechildren, plasma infusion (abst) 206favorable outcome (abst) 203intravascular platelet activation 10710 year follow-up (abst) 1034
Hemorrhagehypotensive, ANF prevents renal dysfunction (abst)... 369pulmonary (abst) 328
Heparan sulfateproteoglycans synthetized by GEC (abst) 174
Heparinin hemodialysis/hemofiltration 890plasma GH in hemodialysis (abst) 626sensitivity to, eosinophilic patients 24:S-84visceral epithelial cell proliferation (abst) 309
Heparin sulfateincreased glomerular permeability 517
Hepatitis Bglomerulonephritis patterns (abst) 143
Herpes zoster in dialysis (abst) 227Hexose monophosphate shunt (abst) 396Heymann nephritis
albuminuria causes lysozymuria 787eicosanoid synthesis, antibody binding (abst) 251indomethacin (abst) 624ligand for autoantigen GP600 (abst) 160passive, anaphylatoxin C5A (abst) 755role of GP330 (abst) 31015-deoxyspergualin (abst) 324
Histamine, permeability (abst) 250Histones, immune complex (abst) 324History, uremia 1013HIV
antibodies in Danish dialysis patients (abst) 756associated focal, segmental sclerosis (abst) 330
HormoneADH excess, micropuncture comparison (abst) 141affecting calcium excretion (abst) 140antidiuretic, cobalt action (abst) 260control of division in proximal cells (abst) 175CRF and thyroid (abst) 195effects on NaC1 permeability (abst) 425growth, IGF-1 and function (abst) 205peptide, bicarbonate absorption (abst) 400protein-induced glomerular hyperfiltration 578PTH, vitamin D3 in CRF 1049requirements, hydrolases in PTC (abst) 170responsive glycan-phospholipid (abst) 175sex, in liver disease in ADPKD (abst) 196
thyroid, CRF (abst) 195vasoactive, dietary protein (abst) 260vasopressin and oxytocin binding sites 959
Horseradish peroxidasepermeability of mesangial cell region (abst) 174
HPLC, uremic toxin 24:S-4Human B cell growth factor (abst) 448Human immunodeficiency virus (abst) 205Hybridization, site of RAS (abst) 169Hydergine, CsA induced RF (abst) 1037Hydrogen transport in IMCD (abst) 398Hydrolases
hormonal requirements for sorting (abst) 170Hydrolysis
phosphoinositide, osmolality (abst) 392Hydronephrosis, ANP and GFR (abst) 358Hydroosmosis, AVP (abst) 390Hydroxyeicosatetraenoic acid (abst) 265Hydroxyl radical, ARF, glycerol (abst) 368Hyperaldosteronism
Bartter's syndrome (abst) 146Hypercalcemia
NaCI reabsorption (abst) 424vitamin D3 (abst) 347
HypercalciuriaANP levels in (abst) 340chlorthalidone promotes mineral retention 1140modulation by calcium of urinary inhibitors 1005vitamin D3, Ca (abst) 336
Hypercapniaenhancement of Na-H antiporter (abst) 407Na }{C03 cotransport (abst) 406
Hyperchloremia, CyA (abst) 361Hypercholesterolemia
glomerular disease pathology 498glomerular injury (abst) 377lovastatin (abst) 136
Hypercholoremic acidosisdiabetic ketoacidosis (abst) 1040
Hyperfiltrationfollowing nephrectomy in donors (abst) 761injury not occur in remnant kidney model (abst) 371protein-induced, hormones 578reversal in diabetic (abst) 387
Hyperglycemiaacidosis, glucose reabsorption (abst) 201glycation of albumin in normal and diabetic rats 673K, aldosterone (abst) 214
Hyperlipidemiaand renal injury (abst) 383extrarenal complications of NS 1184treatment reduces injury in obese rats 667
Hypermetabolismphosphate restriction in remnant kidney (abst) 129remnant kidney (abst) 129
Hypernatremiabrain and kidney inositol (abst) 435trimethylamines (abst) 194
Hyperoxaluria, transplantation (abst) 209Flyperparathyroid bone remodeling, RF 934Hyperparathyroidism
calcitriol deficiency in CRF 722hormonal disorders in CRF (abst) 133
Hyperperfusionhyperfiltration in proteinuria (abst) 212
lvi Subject Index: Vol. 33
Hyperplastic/atrophic changes in cysts 8Hypersensitivity to dialysis (abst) 224Hypertension
ACTH, renal artery pressure (abst) 430air jet stress in SHR (abst) 298alters PG response to diabetes (abst) 378ambulatory BP monitoring in diagnosis (abst) 308ANF vs. captopril (abst) 277angiotensin II dependent (abst) 382atenolol and exercise (abst) 144atherosclerosis, FSGS 917BP and vasopression (abst) 294BP, family history, Na transport (abst) 293Ca, P and vitamin D in essential (abst) 627calcitriol synthesis decreased in SHR (abst) 304calcium administration (abst) 300captopril, renal artery stenosis (abst) 292cation excretion (abst) 297cerebrospinal fluid and CSF Ca2 (abst) 297changes in calcitriol in SHR (abst) 294chronic hypernatremic dehydration (abst) 307dietary Ca and Fe interaction on hematocrit (abst) . . . . 302dietary NaCl restriction vs. diuretic therapy (abst) . . . . 292digoxin-like material levels (abst) 307diphenyithiazole, ADPKD 1130DOC-salt, nifedipine (abst) 374DOCA salt treatment on urinary prostaglandins 930dopamine 1 defect (abst) 306doxazosin and hemodynamics (abst) 144
enalapril on proteinuria (abst) 295genetic susceptibility to cyclosporine induced (abst) . . . 293genetics, enalapril and HCTZ in dogs (abst) 293hemodynamics in natriuresis of essential 875hyperinsulinemic glucose (abst) 298idiopathic membranous nephropathy, untreated 708impaired Ca efflux (abst) 300in Jordanian children (abst) 305injury, high K diet (abst) 307low sodium diet, H20 balance, enalapril (abst) 292Na-lithium counter transport (abst) 307nephrotoxic serum nephritis 53niledipine and vasoconstriction (abst) 294no true sublines of WKY rats in US (abst) 300PGE2 production in diabetic rats with 1100platelet cytosolic Ca (abst) 303post-transplant, captopril (abst) 441preceding neonatal thrombosis (abst) 145
proteinuria in IgA nephropathy 716recombinant erythropoietin (abst) 207renal disease, salt-sensitive Dahi rats 1119
renal plasma flow predicts captopril response (abst) . . . 294spontaneous, glucose intolerance (abst) 296time course of PT response to (abst) 409vascular reactivity and wall/lumen ratios (abst) 305vitamin D3 in essential (abst) 627vitamin D3, Ang 11 receptor sites (abst) 304volume and neural alterations in pre- (abst) 299
Hypertonic hemodiafiltration 24:S-132Hypertrophy
diabetic kidney, enzymes (abst) 376early gene expression (abst) 168
epidermal growth factor (abst) 387glomerular sclerosis (abst) 327sclerosis (abst) 377vasopressin (abst) 264
HyperuricemiaAPKD (abst) 211
HypervolemiaANP and response to (abst) 281
Hypoalbuminemiaextrarenal complications of NS 1184
Hypocalcemiaphosphorus handling (abst)
HyponatremiaAIDS and ARC (abst)correction of symptomatic (abst).electrolytes (abst)in women with diabetes (abst).rapid correction (abst)sexual difference in survival (abst)31P-NMR to study (abst)
Hypophosphatemiax-linked, glucose metabolism (abst) 388
Hypoproteinemiasodium excretion after salt loading (abst) 1034
Hypotensioncaptopril, GFR (abst) 305dialysis, vasopressin (abst) 222lysine vasopressin (abst) 229
Hypothyroidism, ANP (abst) 290Hypouricemia
diabetic, clinical nephropathy (abst) 208Hypovolemia
extrarenal complications of NS 1184Hypoxemia
dialysis induced 24:S-57theophylline and hemodynamics 1078
HypoxiaAng II and ARF (abst) 354glutathione depletion (ahst) 363metabolic responses of RPT, anoxia (abst) 390
Hypozincemia, zinc balance, uremia 1091
Idiopathic hypercalciuriachiorthalidone promotes mineral retention 1140
Idiopathic membranous nephropathynatural history of untreated patients 708
Idiopathic nephrotic syndromeCsA in (abst) 1035serologic tests in diagnosis (abst) 194
Idiopathic renal vasculitisrisk factors in (abst) 213spectrum and outcome (abst) 214
IgAglomerulonephritis and pregnancy (abst) 136rheumatoid factor (abst) 134serum polymeric, in mesangial IgAN (abst) 137
IgA glomerulonephritispolymorphism of immunoglobulin (abst) 330
IgA nephropathyage and disease diagnosis (abst) 196anti-endothelial cell antibodies (abst) 334blood rheology (abst) 134children (abst) 181cyslosporine A (abst) 131
immune complexes model (abst) 326interleukin-2 increased (abst) 331lambda light chain IgA production (abst) 131lambda light chain synthesis 584proteinuria 716proteinuria and prognosis (abst) 203
211186186179210180178
Subject Index: Vol. 33 lvii
cellular immunoregulation (abst) 134
Clq binding, SLE (abst) 333Imipenem in treatment of CAPD (abst) 759Immune complex
antigen binding in glomerular capillary wall (abst) 310clearance by excess antigen (abst) 320deposits, platelets, GN (abst) 318erythrocyte IC clearing mechanism (abst) 311
formation, antibody (abst) 312histones (abst) 324IgA nephropathy (abst) 326lupus erythematosus (abst) 315noncationized antibodies (abst) 315non-H-2 gene (abst) 312
Immune depositclearance (abst) 316quantified 897SP4O,40 (abst) 137
Immune response, interleukin 2 (abst) 319Immunity, mucosal (abst) 329Immunoglobulin, mononuclear cell (abst) 318Immunogold technique, hematuria (abst) 138Immunosuppression
CsA, prednisone, AZA in cadaveric transplants(abst) 440
low dose CsA (abst) 445Indians, American, MGN (abst) 195Indium-Il 1-leucocyte scan, RD (abst) 223Indomethacin
antiproteinuric effect in nephrotic (abst) 381Heymann nephritis (abst) 624permselectivity in nephrotoxic serum nephritis (abst) . . 381proliferation of mesangial cells (abst) 309
Infectiongram negative, CAPD (abst) 249interleukin-l induces natriuresis 1059
Injuryabdominal aneurysm repair (abst) 623BP treatment, ACE inhibitor or Ca inhibitor
(abst) 129Ca-induced mitochondrial (abst) 362calcium channel blockers, capillary pressure (abst). . . . 370CE! and protein restriction (abst) 386cell Ca overload (abst) 359CsA induced chronic nephropathy 590cystic kidneys 610dietary sodium restriction, diuretics (abst) 292elastase mediates glomerular (abst) 312Fc receptor for IgG (abst) 322focal and segmental GS: analogy to atherosclerosis. . . . 917free radical-mediated postischemic, glutathione 843GBM necrosis and crescent organization 966glomerular, tumor necrosis factor (abst) 311
glomerulonephritis, reactive oxygen species (abst) . . . . 130glycine protects (abst) 357hyperfiltration, remnant kidney model (abst) 371hyperlipemia (abst) 383hyperlipidemia treatment reduces 667immune, diet, age and sex affects renal response to ... 561
ischemic, PGE2 (abst) 281
K permeability precedes, by HgC12 (abst) 354oxidant stress following ischemia 812PGE2 production in diabetic rats with hypertension... 1100polyethylene glycol (abst) 364progressive GS (abst) 374
proteinuria in IgA nephropathy 716reduced nephron mass and hypercholesterolemia
(abst) 377signal transduction pathway (abst) 324single kidney and CsA damage (abst) 443tubular antigen associated renal disease (abst) 131
x-ray imaging of gentamicin injury in tubules (abst)Inner medulla
dehydration (abst) 434Inner medullary collecting duct
structural heterogeneity (abst) 432Inositol
brain and kidney during hypernatremia (abst) 435leukotriene D4 binding in mesangial cells (abst) 253MDCK cells, transport (abst) 167tris, tetrakisphosphate pathway in CT (abst) 1711,4,5-trisphosphate, Ca2 channels in PTC (abst) 171
Instruments for BP measurement (abst) 145Insulin
apical, basolateral receptors (abst) 177hypertension and sensitivity to (abst) 298paradoxical hemodynamic effects (abst) 410proteolysis (abst) 396release from pancreatic islets 1066uremic plasma on RBC, receptor (abst) 378
Insulitisanti-interleukin-2 receptor antibody (abst) 321
Interferon gamma, murine lupus (abst) 316Interleukin
hypothesis in hemodialysis 24:S-27Interleukin- 1
altered in RD (abst) 216collagen synthesis in GEC (abst) 317endotoxin-like, in vitro dialysis 29gene expression in lupus nephritis (abst) 150natriuresis in conscious rats 1059proximal tubular glucose transport (abst) 319relevance in HD patients 24:S-21signal transduction pathway (abst) 324
Interleukin-2anti-, insulitis (abst) 321chimeric toxin (abst) 319mononuclear cells, IgAN (abst) 331
Interstitial gradient, excision (abst) 437Interstitial nephritis
CsA, development of immune-mediated 1113protein overload (abst) 313
intoxication, lead (abst) 143intracerebroventricular manassantin
renal function (abst) 437iron defficiency in dialysis (abst) 226[schemia
adeno sine deaminase inhibition (abst) 367allopurinol (abst) 396altered glutathione content (abst) 365ANF and dopamine (abst) 259antioxidant therapy (abst) 353course and pathogenesis in post (abst) 369epithelial polarity (abst) 367exogenous adenine nucleotides (abst) 355Na/K ATPase activity following (abst) 358organic anions, PAH, caphalothin on GFR (abst) .... 1039oxidant stress following 812oxygen free radical (abst) 354protein restriction, reduce cell injury (abst) 352
lviii Subject Index: Vol. 33
restoratin of renal ATP (abst) 396theophylline in ischemic ARF 24transplantation in Brown Norway rats (abst) 441
Ischemic acute renal failurefurosemide (abst) 361
histopathology (abst) 366Ischemic renal failure
CsA effect on (abst) 449human ANF in dogs (abst) 363low hematocrit, splenectomy (abst) 362
Isolated perfused tubule, superperfusion 1009Isolation of glomeruli, immune deposits 897Isoreceoptor IB, Na absorption (abst) 171
Isovolumetric regulation (abst) 438
Jugular catheters (abst) 218Juxtaglomerular distal tubule
MPGN (abst) 1037
Kidneystandard nomenclature
Kidney growth, protein intake 662
Kidney, singleagenesis vs. nephrectomy (abst) 195
Kinase C and renal growth (abst) 151
Kininases, mineralocorticoid, MCD (abst) 288K9/9 antibody induces proteinuria 831
L-dopa effect, Na-K pump (abst) 259L-thyroxine, TAL (abst) 362
L-triiodothyronine, Na-H (abst) 177Lactate
metabolism by TAL (abst) 395
Lambda light chain IgA (abst) 131
Lamininheterogeneity of in GBM (abst) 149
LDL catabolism, cholestyramine (abst) 384Lead
in bone with dialysis 601increases RBC Na!Li countertransport (abst) 293intoxication (abst) 143renal function risk (abst) 190
Lectinglomerular cells, staining (abst) 159
myeloma cast nephropathy (abst) 332Lesion
analysis of, after transplantation, CsA (abst) 448
catecholamine receptor binding, aging 1073
circulating DNA and lupus nephritis 487glomerular tip in NS (abst) 145glutathione transferase in the urine 571HD associated subclavian vein stenosis 1156
hypercholesterolemia 498interstitial nephritis in PAN nephrosis 14
liver; APKD (abst) 192
skeletal caused by f32-microglobulin amyloidosis(abst) 756
Leukemianephrotic syndrome in chronic lymphocytic (abst) 207
Leukopeniaxanthine oxidase deficiency (abst) 208
LeukotrieneB4, acute nephrotoxic serum nephritis (abst) 275D4 binding (abst) 253role of protein kinase C (abst) 254
Life plan, overview Marrakech meeting 24:S-2
Life support, withdrawing (abst) 758Light chain-related disease 881
Light chainsIgAN 584plasma exchange in ARF due to multiple myeloma . . . 1175
Lindane in uremics (abst) 199
Lipiddeposition, hypercholesterolemia 498ESRD(abst) 216lipoprotein alterations in nephrotic syndrome (abst) . . . 179membrane, erythrocyte cation transport (abst) 227
Lipopolysaccharide (abst) 316
Lipoproteinin children on CAPD (abst) 248
metabolism, lovastatin therapy in hyperlipidemia 1160
Lipoxygenaseactivity in HD (abst) 240during HD 24:S-80
Lisinoprilpharmacokinetics in CRF (abst) 142
Lithiumbiphasic effect (abst) 263clearance in man and dog (abst) 1034
nephrotoxicity 145tubular site of action of diuretics (abst) 1036
vasopressin sensitive adenylate cyclase (abst) 2656 and 7, renal failure (abst) 357
Liver disease, Na taurocholate 782LLC-PK1
intracellular pH (abst) 405
Na dependent transport system (abst) 438
vasopressin (abst) 161
Lovastatinhypercholesterolemia (abst) 136
therapy in nephrotic hyperlipidemia 1160
Lupus erythematosusclearance of pathogenic immune complexes (abst) 315
Lupus glomerulonephritismetabolism of C3 and C4 (abst) 130
Lupus nephritisanti-phospholipid antibodies (abst) 328
aspirin (abst) 281circulating DNA and 487dialysis and transplantation in ESRD (abst) 140
interleukin 1 gene expression (abst) 150
intravenous pulse cytoxan (abst) 179myocardial infarcts associated with SLE (abst) 132polyreactive anti-DNA antibodies (abst) 331
prediction of outcome (abst) 331
serological changes in severe (abst) 186
survival patterns in ESRD (abst) 212Lympho-monokine abnormalities (abst) 627Lymphoid cells after dialysis membrane 24:S-53
Lysine vasopressinHD induced hypotension (abst) 229
Lysozymuriacaused by albuminuria in Heymann's nephritis 787
Macronutrients, BP (abst) 309Macrophage chemotaxis (abst) 323Macula densa
mesangial cell region permeability to HRP (abst) 174
signal, renin (abst) 256
Magnesiumcontrol mechanisms for excretion of (abst) 140
diuresis in rats (abst) 141
Subject Index: Vol. 33 lix
lithium-losing nephropathy (abst) 146plasma, conservation of during Mg deprivation
(abst) 345urinary wasting, CsA treatment (abst) 451
Magnetic resonance imagingkidney transplant dysfunction (abst) 1040
MaleateCa uptake in microsomes (abst) 165
Manassantin on renal function (abst) 437Mannitol
induced ARF (abst) 188Marrakech meeting re: renal failure 24:S-2MDCK
bradykinin Ca2 transients (abst) 153inositol transport (abst) 167membrane fluidity asymmetry (abst) 163pertussis toxin and cAMP (abst) 170PGE induced elevation in Ca2 concentration (abst)... 148
Mean arterial pressure, CAVH math model 685Medulla
electrolyte, urea and water transport (abst) 427purine nucleotide cycle (abst) 393
Medullary collecting ductacetazolamide effect on kinetics (abst) 406
MembraneAl removal, membranes compared 24:S-17lAN 69 in hemodiafiltration 24:S-135anaphylatoxins C3a and C5a adsorption (abst) 226AN69S in CAVH 24:S-150artificial, thromboxane release 24:S-75binding of complement (abst) 218compared in ESRD treatment 24:S-44complement activation and biocompatibility (abst) . . . . 230eosinophilia in HD 24:S-73GBM necrosis and crescent organization 966glomerular basement, pressor effects (abst) 295granular and basal cell, particle arrays (abst) 172luminal, water permeability (abst) 269lymphoid cells after contact with 24:S-53perfusion of human peritoneum (abst) 249peritoneal, plasticizer exposure (abst) 246peritoneal, transport properties of 24:S-107potential depolarized by Cl (abst) 168superoxide in cuprophane (abst) 224syndromes associated with use 24:S-49
Membranoproliferative glomeruloscierosisinflammation of JG distal tubule (abst) 1037
Membranous glomerulonephritis 627cyclophosphamide and prednisone (abst) 185predictors of progression (abst) 183
Membranous glomerulopathyanti-laminin autoantibodies (abst) 309
Membranous nephropathycomplement C5b-9 excretion (abst) 331heparan sulfate changes, increased glomerular
permeability 517natural history of untreated patients 708predicting renal failure (abst) 200transport of C5b-9 by GEC (abst) 319
Mercury induced MGN (abst) 309Mesangial cell
desmin as a marker (abst) 158indomethacin (abst) 309proliferation by PGE2 (abst) 276proliferation, PGE2 and matrix synthesis (abst) 268
replication, AVP (abst) 286synthesis of PAF (abst) 273relaxation of, ANP, NaNpr, cGMP (abst) 285voltage-sensitive Ca channels (abst) 158
Mesangial immunoglobulin, alcohol (abst) 385Mesangialproliferative GN
SW American Indians (abst) 195Metabolic acidosis
Ca efflux from bone (abst)glucocorticoid (abst)phosphorus deprivation (abst)vitamin D3 synthesis, Ca overload (abst)
Metabolic alkalosischloride depletion (abst)
Metabolismgluconeogenic (abst) 395glycolytic (abst) 395lactate (abst) 395pyrimidine nucleotide (abst) 390
Metalloproteinases, GBM (abst) 310Methylguanidine, ARF, CRF (abst) 371Methylprednisolone, CsA (abst) 454MHC molecules, T lymphocytes (abst) 454Microalbumin, diuretics (abst) 192Microalbuminuria
enalapril (abst) 209GFR in diabetes (abst) 189
Microcytic anemia, RBC-Al (abst) 349Micronephrocalcinosis (abst) 435Microperfusion, isolated tubule 1009Micropuncture
serial analysis of SNGFR in renal ablation 855Microscopy, glomerular size (abst) 325Mineral homeostatic system (abst) 350Mineralocorticoid
acidification defect in tubular acidosis (abst) 130effect on kininases in MCD (abst) 288escape, ANF (abst) 430
Minimal change nephrotic syndromecyclosporine (abst) 329no changes in (abst) 196
Monocarboxylates in kidney (abst) 388Monoclonal antibodies
alkaline phosphatase in kidney (abst) 176anti-DNA antibodies (abst) 323anti-OKT3, cytomegalovirus infections (abst) 444epitope specific induction of proteinuria 831intercalated cells, isolation by 543nonGBM glomerular capillary wall antigens (abst) 144SGP-l 15/107, proteinuria induced 818
Monoclonal light chain-related disease 881Mononuclear
cells, heart graft survival (abst) 445phagocytes, GN (abst) 135
Morality, withdraw life support (abst) 758Morphology
of renin synthesis (abst) 145mRNAs localize RAS (abst) 269Mucormycosis
deferoxamine therapy in dialysis (abst) 238Multiple myeloma
plasma exchange in ARF due to 1175
Muramyl-dipeptide (abst) 439Murine chronic graft disease (abst) 311Murine interstitial nephritis (abst) 158
351397335342
IX Subject Index: Vol. 33
Murine lupus nephritisinterferon-gamma (abst) 316I 5-deoxyspergualin (abst) 322
Murine placental listeriosis (abst) 447Muzolimine, K conductance (abst) 424Myelofibrosis, transplantation (abst) 447Myeloma cast nephropathy
lectin and chemical studies (abst) 332monoclonal antibodies to THP (abst) 328
Myo-inositol, diabetes (abst) 372Myocardial infarction
natriuresis (abst) 205Myocardial infarcts
associated with SLE and lupus inhibitor (abst) 132Myocardial interstitial fibrosis
experimental uremia 804Myocytes in fish, ANP secretion (abst) 253Myogenic autoregulation, TGF (abst) 412Myristyl acylation, endotoxin (abst) 151
Na-K ATPaseactivity in BB diabetic rats (abst) 420cell rubidium uptake 642glucocorticoid receptors (abst) 155mediators of response (abst) 424ontogenic increase of Na-H exchange (abst) 41502 consumption, Na concentration (abst) 426PG synthesis (abst) 417G-protein modulation (abst) 150
Na/Hantiport, MDCK cells and bradykinin (abst) 153antiporter, lysine group at amiloride binding site (abst). 401exchanger, amiloride (abst) 399
Na/Caexchange, cytosolic Ca (abst) 154
Na, K-ATPaseactivity following ischemia (abst) 358ankyrin and spectrin (abst) 167
antidigoxin antibody (abst) 383oubain, bioluminescent assay (abst) 306PGE2 inhibits in IMCD (abst) 268reversible depression by ACE (abst) 303uremia effect on red cell (abst) 387
Nandrolone decanoate in uremics (abst) 221Natriuresis
acute myocardial infarction (abst) 205ANF secretion, water drinking (abst) 258ANP infusion (abst) 258APKD (abst) 211carotid artery traction (abst) 301diuretic effects of atrial peptide SC-44900 (abst) 290dopamine fails to induce (abst) 410essential hypertension, renal hemodynamics of 875high-output heart failure 656interleukin-l induces 1059nicardipine (abst) 302normal man, oral Ca, K, NE and digoxin (abst) 301oxidized ANF-analog, diuresis (abst) 176pressure, angiotensin (abst) 411pressure, Na balance in NE hypertension (abst) 296renal denervation, PGE2 (abst) 280vasopressin and renal nerves (abst) 266volume expansion, dopamine (abst) 415
Neoplasiahematuria (abst) 187
uremia corrected by dialysis (abst) 622
Neopterin levels, allograft (abst) 453Nephrectomy
adenosine nucleotides in azotemic rabbits (abst) 382chronic renal denervation (abst) 414dietary protein (abst) 353dietary protein on DNA (abst) 380fluid intake on progression of CRF (abst) 381glomerular hyperfiltration following (abst) 761glomerular procollagen mRNA (abst) 370growth promoting factors (abst) 392infant glomerular adaptation (abst) 409procoagulant and fibrinolytic activities (abst) 384reserve filtration capacity (abst) 1033sex vulnerability in GS (abst) 378vs. agenesis (abst) 143
Nephritogenicityanti-heparin sulfate-proteoglycan antibodies (abst) 320
Nephro-thyreo-arthropathia (abst) 761Nephrocalcin
crystal aggregation, surface charge (abst) 340purification (abst) 340renal cell cardinoma (abst) 209
Nephrologists, clinical competence 608Nephron
cell rubidium uptake 642deep, more vulnerable to renal mass ablation (abst) . . . 374juxtamedullary responds to perfusion pressure (abst) .. 409
proteinuria (abst) 325
Nephropathologyoverview of pediatric 1016
Nephropathyanalgesic syndrome (abst) 136congenital magnesium and lithium losing (abst) 4±6heroin associated, transplantation (abst) 442obstructive, recovery from 775risk in diabetes (abst) 193
Nephrosisalbumin synthesis (abst) 379clotting factors in (abst) 210protein restriction, ACE (abst) 188
Nephrotic hyperlipidemialovastatin therapy 1160
Nephrotic syndeomePAN nephrosis 14
AVP volume relationships (abst) 211CsA induced remission in children 729cyclosporine in chi1dren (abst) 185extrarenal complications of 1184
gemfibrozil, hyperlipidemia (abst) 192
glomerular tip lesion (abst) 145IgG subclass depression in children (abst) 333indomethacin (abst) 381lipid and lipoprotein alterations (abst) 179lovastatin therapy in hyperlipidemia 1160
lymphocytic leukemia (abst) 207no change (abst) 196PGE2 and 6-keto-prostaglandin Fla (abst) 760phospholipids (abst) 628plasma volume and ANP (abst) 261
prednisolone increases glomerular permeability 1169
serologic tests in idiopathic (abst) 194variability of C4 gene number (abst) 165
Nephrotoxic nephritisrenal fibrosis (abst) 321
Subject Index: Vol. 33 lxi
Nephrotoxic serum nephritisindomethacin (abst) 381leukotriene B4 (abst) 275with hypertension 53
NephrotoxicityAIDS patients receiving pentamidine (abst) 198aminoglycoside 900aminoglycosides-induced in rat neonates 36contrast (abst) 208CsA in children (abst) 214CsA induced remission in children 729electrolyte composisiton of tubular cells in
gentamicin 1107genes encoding growth factors (abst) 365gentamicin cortical uptake (abst) 355HgC12, glycerol induced ARF (abst) 352infusion rate on CsA (abst) 442lithium in rabbits (abst) 145model of CsA (abst) 443reduction of CsA, 16-dimethyl prostaglandin E
(abst) 452uranyl fluoride induced (abst) 370
Nervechronic renal denervation (abst) 414conduction velocity, ESRD (abst) 241renal regulation of Na-H antiporter activity (abst) 420role in heart failure (abst) 418
Netilmicin toxicity in rat neonates 36Neuron disease, axonal conduction (abst) 625Neuropeptide Y inhibition (abst) 252Neutrophil
down regulation, HD (abst) 241migration, HD 24:S-86
New Zealand GN survey (abst) 133Nicardipine, renal effects (abst) 302Nifedipine
glomerular injury in hypertension (abst) 374propanolol, transplantation with CsA (abst) 367vasoconstriction in hypertension (abst) 294
NI}{3T3 cells, bone resorption (abst) 349Nisoldipine
progression of CRF (abst) 189Nomenclature, standard for the kidneyNorepinephrine
adrenergic receptors in CRF (abst) 295ANP reverses vasoconstriction (abst) 273brain synaptosomes in CRF, role of PTH (abst) 385CsA and vasoconstrictor effects of (abst) 442Na balance (abst) 296
Novobiocin, Na transport (abst) 416Nuclear magnetic resonance (abst) 397Nucleotide metabolism, protein (abst) 389Nutrition
urea kinetics applied to (abst) 215zinc deficiency and uremia 1091
Obstruction, ureteral, recovery of 775OKT3
rejection (abst) 327Oligonucleotide, Na-K ATPase (abst) 156Organelle, cell division (abst) 149Osmolality
hydrolysis (abst) 392luminal fluid, cytosolic Ca concentration (abst) 150
Osmolytedehydration in TM (abst) 434
levels in PCT (abst) 431Osmoregulation, sorbitol in medullary 635Osmotic agents for peritoneal dialysis 925Osteodystrophy
CrEDTA/TcMDP ratio (abst) 139vitamin D and keto acids (abst) 132
OsteomalaciaPTH on Al induced (abst) 343renal failure (abst) 187
Osteoporosiscalcitriol (abst) 345
Ouabainbioluminescent assay (abst) 306mediators of NaK ATPase response (abst) 424
Overdose, treatment of 735Oxalate
Ca dependent functions of mitochondria (abst) 174in HD (abst) 198vitamin C (abst) 382
Oxidative stress, pH, Ca2 (abst) 157Oxygen
consumption and oxidant stress, protein (abst) 381consumption by peritubular protein (abst) 423consumption, alpha-adrenergic agonist (abst) 392monocarboxylates in vivo (abst) 388
Oxygen free radicalinvolvement in decrease of ATPase activity 1038ischemia (abst) 354
Oxytocinreceptors, LLC-PK1 cell (abst) 173
vasopressin binding sites 959Ozolinone effect in dog (abst) 280
Pancreas, insulin release, CRF, PTH 1066Papillary collecting tubule
myo-inositol tris-, tetrakisphosphate pathway (abst) ... 171
osmolyte levels (abst) 431Para-aminohippuric acid, diabetes (abst) 389Paracentesis, ascitis (abst) 207Paraminohippurate
gamma glutamyltransferase ammoniagenesis (abst) . . . . 397Parathormone levels, Ca therapy (abst) 452Parathyroid
vitamin D3 on cytosolic Ca in dispersed cells 850Parathyroid glands, uremia (abst) 335Parathyroid hormone
acidification by PCT (abst) 169activation of Ca2 messenger system (abst) 341age, number of receptors (abst) 348Al activity in transplantation (abst) 346Al infusion (abst) 336alpha-hydroxylase activity (abst) 338ammoniagenesis in proximal tubule (abst) 389analog, proximal HCO3 (abst) 341Ca changes, Al bone disease after DFO (abst) 345calcitriol (abst) 339changes from ionized Ca (abst) 337CRF, fatty acids oxidation in skeletal muscle 555CRF, insulin release from pancreatic islets 1066desensitization of Ca2 response (abst) 340desferrioxamine, Al bone disease (abst) 221GTP-binding proteins (abst) 344HD, erythropoietin (abst) 224hypercalcemic dialysis, Al levels (abst) 345in uremia (abst) 219inhibits Na/H exchange (abst) 298
lxii Subject index. Vol. 33
level and BP in humans (abst) 308lymphocyte in uremics (abst) 197norepinephrine metabolism in brain (abst) 385secretion during renal failure (abst) 627skeletal response to calcemic action (abst) 341uremia, Al, Ca and change of Ca (abst) 337vitamin D3 CRF 10491-34 and 1-84 binding sites (abst) 3388-Br-cAMP effect on Ca2 (abst) 343
Particle arrays in membrane (abst) 172Particulate guanylate cyclase (abst) 266PC-12 cells, genes (abst) 162PDGF, growth, pH and Ca (abst) 156Pentamidine, nephrotoxicity (abst) 198Peptide
mitogens, regulate DNA synthesis (abst) 318mouse and bovine homology 652muramyl-dipeptide (abst) 439natriuresis after carotid artery traction (abst) 301
Perfusionpressure changes and juxtamedullary nephron (abst). . . 409nephrotoxic serum nephritis 53
Pericarditis 24:S-10Peritoneal dialysis
heteroporosity model (abst) 243phosphatidylcholine (abst) 247, 248two catheters compared (abst) 250volume effect on lymphatic flow (abst) 247volume measurements 64
Peritonitisaseptic in CAPD (abst) 142CAPD (abst) 133risk factors in CAPD (abst) 244vancomycin superior to cefazolin in CAPD (abst) 245
PermeabilityADH on butanol (abst) 434experimental models (abst) 135fluorescence measurement of transepithelial water
(abst) 435histamine and antagonists (abst) 250increase with heparan sulfate changes 517NaCI and osmotic water, vasopressin (abst) 280Osmotic water, ANF (abst) 278perfusion of human peritoneum (abst) 249water and membrane fluidity in toad bladder (abst). . . . 164water, of luminal membrane (abst) 269
Permselectivityin diabetes 100polyanion neutralization (abst) 414
Pertussis toxinblocks a2-adrenoceptor vasopressin action (abst) 264cAMP, bradykinin (abst) 170endotoxin stimulates PGE2 (abst) 289somatostatin inhibition 536vasopressin (abst) 257
pHbicarbonate secretion (abst)Ca2 in oxidative stress (abst)C1 base exchange regulates (abst)intracellular, single LLC-PKI cells (abst)luminal, and AVP effect on K secretion (abst)measurement of intracellular, K depletion (abst)Na/H antiporters regulate (abst)NH3 metabolism in LLC-PK1 cells (abst)regulation of cell (abst)
steady state intracellular (abst) 403Phi determination in cells (abst) 163Phorbol esters
contract VSMC (abst) 303Na-H antiporter (abst) 428transport (abst) 415
Phorbol myristate acetate (abst) 265acetate, A23 187 (abst) 252
PhosphateAl, ESRD 24:S-172binder, calcium carbonate 24:S-l84bone turnover, I ,25-dihydroxycholecalciferol,
binders 989calcium citrate in treatment of CRF 95depletion, measurement of intracellular pH (abst) 394depletion, taurine (abst) 432hyperfiltration, somatostatin (ahst) 279metabolic alkalosis (abst) 401Na excretion, ANP (abst) 279phosphonoformic acid inhibits (abst) 348protein restriction (abst) 351PTH-independent uptake, Ca (abst) 348reabsorption, growth hormone (abst) 344restriction, hypermetabolism in remnant kidney
(abst) 129transfer in bladder, time studies 58transport kinetics (abst) 436transport, Na and pH dependent (abst) 346uptake, sodium dependent (abst) 155vitamin D3 stimulates uptake (abst) 350zinc depletion and low diet of (abst) 342
Phosphatidyicholine synthesis (abst) 248Phosphatidylinositol cascade (abst) 360Phosphoenolpyruvate carboxykinase
localization of acidosis-induced (abst) 177Phosphoi nositide
changes, Ang II (abst) 253hydrolysis, carbachol in inner medullary CD (abst).. .. 165turnover, transduction mechanisms (abst) 153
Phospholipase A2acetate (abst) 265GTP binding protein (abst) 154
Phospholipase Cgentamicin (abst) 362MDCK cells (abst) 170
Phospholipidalterations, damage in childhood NS (abst) 628content of BBMV, Al (abst) 350
Phosphonoformic acidPi uptake (abst)solute (abst)
Phosphorusdeprivation in rabbits (abst)hypocalcemia (abst)metabolic acidosis (abst)regulates vitamin D3 (abst)
Phosphorylationrenal growth (abst) 159
PlasmaANP disappears in dogs (abst)catecholamines, RF (abst)clearances in diabetes (abst)exchange, complement activation (abst)Mg deprivation (abst)volumes, colloid osmotic gradient, diabetes (abst)
344160
337339335346
402157399405426394403394403
275410187756345194
Subject Index: Vol. 33 lxiii
Plasminogen activatoractivity 868endothelial (abst) 176inhibitor (abst) 330vasoactive (abst) 157
Plasticizers, scierosing (abst) 624Platelet activating factor
All causes formation of (abst) 278calcium channel blockade (abst) 413mesangial cell synthesis (abst) 273microcirculatory responses (abst) 260multiple signaling pathways (abst) 161
permeability to proteins (abst) 280role in endotoxemic ARF (abst) 358vascular smooth muscle cells (abst) 171
Platelet activation in HUS 107Platelet arginine vasopressin
AVP in diabetes (abst) 180Platelet derived growth factor
EGF stimulate prostanoid synthesis (abst) 162Platelets, calcium in (abst) 300Plethysmography in HD (abst) 228PMN-leukocytes, transplantation (abst) 455Poison
teatment of overdose 735uremic toxins 24:S-4
Poly-L-lysine, eicosanoid (abst) 282Polyamide hemofilter (abst) 237Polyanion, heparan sulfate 517Polyaspartic acid, gentamicin (abst) 353Polycystic kidney disease
cystic kidneys 610experimental, tubular originated renal changes 8tissue culture (abst) 191
Polyelectrolytes in peritoneal dialysis 925Polyethylene glycol, injury (abst) 364Polyglobulism and CsA (abst) 452Polymeric IgA in IgAN (abst) 137Polymorph superoxide production (abst) 248Polymorphism, IgA GN (abst) 330Polymorphonuclear granulocytes (abst) 625Polymorphonuclear leukocytes (abst) 369Polysulfone
high flux dialysis membrane (abst) 239Potassium
adaptation, aldosterone (abst) 427aldosterone and kaliuresis after loading of (abst) 1037aldosterone role in high intake (abst) 270ammonia production by PT (abst) 405
225
hyperglycemia (abst) 214hypertensive injury (abst) 307mechanism of adaptation (abst) 418mechanism of aldosterone induced increase (abst) 429multiple pathways for transport (abst) 429permeability precedes injury by HgCl2 (abst) 354
permeability, uranyl nitrate (abst) 354plasma renin activity directly related to (abst) 288reversible Cl dependent flux (abst) 429stretch-activated channels (abst) 425vaspressin enhances secretion of (abst) 426
Potential, measurement of BM (abst) 420Predictors of GN outcome (abst) 143Prednisolone
conversion to alternate day therapy (abst) 449glomerular permeability to proteins in NS 1169
PregnancyANF plasma concentrations in (abst) 140ANF, aldosterone and plasma volume (abst) 257chorionic gonadotropin (abst) 260hypertension and plasma renin activity (abst) 306IgA glomerulonephritis (abst) 136membranous glomerulonephritis (abst) 132renal functional reserve (abst) 206successful in transplant recipients (abst) 441successful outcome, hemodialysis (abst) 132Tamm-Horsfall glycoprotein excretion (abst) 203
Pressor effects on GBM (abst) 295Prevention, progression of renal disease 116Procoagulant
activity of macrophages in GN (abst) 130activity in GN (abst) 134in remnant kidney (abst) 384
Procollagen mRNA, nephrectomy (abst) 370Progressive glomeruloscierosis
chronic serum sickness (abst) 1037Progressive renal disease
rational therapeutic principles 116Progressive renal failure
new antibody-antigen system (abst) 333'251-iothalamate clearance, creatinine (abst) 190
Propionate, cell swelling (abst) 418Prostacyclin production, cAMP (abst) 271Prostaglandin
ammoniagenesis in acute respiratory alkalosis (abst)... 401ANF antagonizes release of (abs) 279blockade in denervated kidneys, captopril (abst) 277cAMP and Ca2 signaling systems (abst) 271Ca2, bradykinin in arterioles (abst) 261DOCA salt treatment on urinary 930GFR, albumin in diabetes (abst) 199glomerular production, GN (abst) 264glucagon, mediates amino acid induced rise in
hemodynamics 1147hydronephrotic kidney sensitivity to bradykinin 71hydroxyeicosatetraenoic acids (abst) 265interleukin-l induces natriuresis 1059mesangial cell proliferation, matrix synthesis (abst). . . . 268modulate mesangial cell proliferation (abst) 276Na-K ATPase activity (abst) 417PTH mediated Ca transients (abst) 351
vasopressin antagonists (abst) 251verapamil, GFR and CyA administration (abst) 355
Prostaglandin E1reversal of proteinuria (abst) 321
Prostaglandin E2cytoprotective effects of (abst) 281
epidermal growth factor mechanism (abst) 274inhibits Na-K-ATPase in IMCD (abst) 268production in diabetic rats with hypertension 1100renal denervation, natriuresis (abst) 280
bath, dialysis (abst)Cail channels in mesangial cells (abst)cell rubidium uptake indexes transport ofchannels in papillary surface epithelium (abst).C1 channel currents in BLM (abst)conductance, muzolimine (abst)depletion alkalosis, PHCO3 (abst)depletion and vasopressin (abst)depletion causes Na retention, high BP (abst)depletion, metabolic acidosis (abst)
164642424428424402431299405
lxiv Subject Index: Vol. 33
6-keto-prostaglandin Fla in NS (abst) 760Prostaglandin F2a
cytosolic pH, mesangial cells (abst) 154Protein
adriamycin nephrosis (abst) 380albumin synthesis (abst) 378alimentary, phosphorus restriction and CRF (abst) . .. 1041analysis of efferent arteriole serum, electrophoresis. .. 1181BP in diabetic nephropathy (abst) 190cell injury in ischemia (abst) 352complement, SP4O,40 in immune deposits (abst) 137
dexamethasone, heparan sulfate peoteoglycan (abst)... 161diabetic nephropathy, restriction of (abst) 184diacylglycerol, kinase C, transport of fluid and K
(abst) 272diet affects response to CyA (abst) 357diet, age, sex affects immune injury 561different sources in healthy humans (abst) 411distinct G, thrombin and growth factor (abst) 160DNA, protein synthesis after nephrectomy (abst) 380drug binding in CRF 996effect of diet on muscle protein synthesis (abst) 353glomerular disease and hypercholesterolemia 498GTP-binding, Ni, cAMP production (abst) 287induced hyperfiltration 578intake, GRF and creatinine generation (abst) 183kinase C modulates bradykinin, MDCK cells (abst).... 169kinase C, activators of (abst) 419kinase C, Ca mobilization (abst) 277kinase C, leukotrienes (abst) 254kinase C, renal growth (abst) 151
kinase C, vasopressin (abst) 153
kinase during diabetic renal growth (abst) 393kinase in glomerular eipthelial cells (abst) 170
kinase, glomerular epithelial cells (abst) 170lipoprotein abnormalities, IDD (abst) 213loss during hemofiltration 24:S-l 14low molecular weight (abst) 365low, diets and CRF (abst) 376membrane, complement activation (abst) 323mitotic response to high intake 662Na-K-ATPase activity modulated by 0-protein 150nucleotide metabolism (abst) 389oxygen consumption and oxidant stress (abst) 381PAF on glomerular permeability to (abst) 280partial sequence of ACE 652pathogenic role in systemic lupus EM (abst) 317
permeability in glomerulopathies (abst) 200phosphonoformic acid binding in BBM (abst) 160
phosphorylation during renal growth (abst) 159
PKD and diet (abst) 315prednisolone increases permeability to, NS 1169purification from BBMV (abst) 398
regulation of 02 consumption (abst) 423renal response to acute meal (abst) 386renin secretion, low protein diet (abst) 275
restriction, phosphate reabsorption (abst) 351
S and 0, clotting in nephrosis (abst) 210serum binding of cephalosporin during CAPD (abst). . . 247stimulation on renal function, CR1 (abst) 1033
urinary epidermal growth factor (abst) 376vasoactive hormones and dietary (abst) 26024-hour renal excretion (abst) 142
Proteinuriaacute All blockade (abst) 383
analgesic nephropathy (abst) 141CsA reduces in anti-GBM nephritis (abst) 1039DNA effect on glomerular deposits (abst) 316enalapril in SHR (abst) 295epitope specific induction of 831high diet carbohydrate (abst) 326hyperperfusion vs. hyperfiltration (abst) 212lgA nephropathy 716IgA nephropathy (abst) 203induction by SGP-1 15/107 818long and short looped nephrons (abst) 325overview of pediatric nephropathology 1016PAN differences in rat strains 524proteases, ON, Avidin A (abst) 313protein overload, TIN (abst) 313reversal, PGE1, iloprost and TSI (abst) 321
thromboxane synthetase antagonist 77tubulointerstitial nephrosis and aminonucleoside
nephrosis 14
type 2 diabetes and prognosis (abst) 197Proteoglycan, 35S labelled (abst) 313
Proteolysisinsulin (abst) 396thyroid hormone, CRF (abst) 391
Proteolytic activity after ICGN (abst) 326Proto-oncogene expression, ARF (abst) 152Proton
NMR imaging, diuretics (abst) 435translocating ATPase in IMCD (abst) 408
Proton pumpclathrin-coated vesicle, structure (abst) 17717 kDa subunit of CCV (abst) 174
Proximal cellshormonal control of division (abst) 175simian virus 40 (abst) 151
PTH and acidification by (abst) 169Proximal convoluted tubule
ionic ammonium exit (abst) 407ontogenic increase of Na-H exchange (abst) 415PTH and acidification by (abst) 169transepithelial Na transport (abst) 421
Proximal tubular cellsangiotensinogen production (abst) 291cAMP, pH1 and cell to cell communication (abst) 164electrophysiology and ultrastructure 508
gene transcription, pH (abst) 169GP330 a matric receptor (abst) 165
hormonal requirements for membrane sorting (abst) . . . 170light chain-related renal disease 881
loop of Henle, ANP effect (abst) 289phosphate transfer in frog bladder 58reflection coefficients (abst) 437single channel recordings (abst) 425stretch activated K channels (abst) 425time course response to hypertension (abst) 409
Pruritus in CRF (abst) 759
Psychogenic polydipsiahyponatremia correction in (abst) 186
Psychology in renal failure patients 24:S-l8Pulmonary artery, C3, C5 (abst) 233Pulmonary mechanics, HD (abst) 220
PumpCa a sytoplasmic inhibitor of Na-K (abst) 622L-dopa effect on Na-K (abst) 259
proton translocating ATPases 767
Subject Index: Vol. 33 lxv
vanadate sensitive, K proton (abst) 423Purine nucleotide cycle (abst) 393Puromycin aminonucleoside
proteinuria (abst)nephropathy, proteinuria and early sclerosis (abst)nephrosis, cholestyramine resin (abst)nephrosis,converting enzyme inhibiton (abst)nephrosis, differences in rat strains
Pyelonephritic renal scarringhypervolemia, hormones and hemodynamics (abst).... 195
Pyelonephritisfree radicals (abst)renal scarring (abst)
Pyrimidine nucleotide metabolism (abst)Pyrogens, MNC-IL-1 productionPyroglutamyl-histidine transport (abst)
Radiocephalic A-V fistulas (abst)Rapidly progressive nephritis
antibodies (abst)RDT, amyloid arthropathy (abst)Reactive oxygen species
do not mediate ischemic ARF (abst)PMN (abst)
Receptorapical and basolateral insulin (abst)beta-adrenergic, two classes of (abst).clearance, of ANF (abst)DA-1, 1251-SCH23982 (abst)down regulation of ANP (abst)
Recombinant erythropoietinabsorption of, peritoneal cavity (abst)HD (abst)quality of life in chronic HD (abst)urea kinetics (abst)
Redycompute, dialysis (abst) 234sorbent dialysis (abst) 238system of dialysis (abst) 220
Rejectionanti-T cell therapy (abst) 447lymphocyte recognition of HLA-A2 (abst) 446OKT3 (abst) 327triple drug therapy in children (abst) 447
Renal ablationSNGFR, micropuncture 855steroids (abst) 377
Renal artery pressurecontrol during hypertension (abst) 430ACE inhibition (abst) 1038ACE inhibition eliminates hippuran (abst) 760
Renal decapsulationabdomen and perinephric effusions (abst) 199
Renal diseasecrack abuse in (abst) 181development of hypertension in salt-sensitive DahI . . . 1119molecular forms of ANP in plasma and urine (abst) . . . 201
Renal failureangioplasty in elderly patients (abst) 203calcitriol deficiency 722captopril, iloprost and OKY 046 (abst) 281chronic ON, severe proteinuria and TIN predict 14contrast media-induced 699contrast nephropathy (abst) 180insulin release from pancreatic islets 1066lithium 6 and 7 (abst) 357
Saline expanded dogs, ANF (abst)Saralasin
cyclooxygenase inhibition (abst)Scarring
escherichia coli (abst)hemodynamics (abst)
Sclerosis
202187
24:S-18410200627198254
hyperfiltration, perfusion, hypertension (abst) 377hypertrophy (abst) 327
plasticizers (abst) 624
761
177276279419287
243240242242
liver transplant patients (abst)osteomalacia due to interstitial nephritis (abst)perception of psychological symptoms
410 plasma catecholamines (abst)379 predicting in membranous nephropathy (abst)376 PTH secretion (abst)373 rapid in AIDS nephropathy (abst)524 reversible, captopril (abst)
skeletal response to PTH (abst) 341solute specific dialysis (abst) 250WR-272l protects against 934
371 Renal function759 decline, diet (abst) 139390 reserve, pregnancy (abst) 206
29 risk of lead workers (abst) 190438 Renal papillary necrosis (abst) 367
Renal pelvis, urea flux (abst) 439Renal plasma flow
BCAA and hemodynamics 91Renal stone disease
Saudi Arabia (abst) 213Renin
acute inhibition of converting enzyme (abst) 757anatomy of secreting cell in AKPKD 1084
angiotensinogen, gene expression (abst) 163atriopeptin III, cGMP (abst) 267cGMP a second messenger of adenosine in inhibition .. . 798CsA effect on release (abst) 274CsA enhances secretion of (abst) 446cyclosporine A hypertension (abst) 267direct measurement in hypertension (abst) 261directly related to dietary K (abst) 288kinins mediate furosemide induced release (abst) 274low protein diet (abst) 275macula densa signal (abst) 256morphological events (abst) 145secretion and production of, isolated JG cells 947selective breeding for response in low Na diet (abst). . . 278serial plasma activity, pregnancy (abst) 306
Renin-angiotensin systemANP (abst) 286asymmetric reduction of Ang II receptor sites (abst). . . 304localization by hybridization of mRNAs (abst) 269saline loading on uranium-induced ARF 942diphenylthiazole develops renal cystic disease 1130
Renoprival nephropathy (abst) 384Renorenal reflexes, SHR (abst) 299Respiration
mitochondrial, cobalt distribution (abst) 152Rheumatoid arthritis
CsA dosage in (abst) 761Rheumatoid factor in IgAN (abst) 134rHuEPO, coagulation disturbances 622Ribonucleic acid, androgen (abst) 262Rubidium, cell uptake 642
266
277
325759
lxvi Subject Index: Vol. 33
thromboxane synthetase antagonist ameliorates 77Segmental glomerulosclerosis
analogy to atherosclerosis 917Serum nephritis
fish oil diet, nephrotoxicity (abst) 322Serum sickness nephritis
T-lymphocytes (abst) 314Severe lupus nephritis
serological changes (abst) 186Sex
differences in baroreflex sensitivity (abst) 411effect of diet, age, immune injury 561NaCI excretion compared in rats (abst) 429
SGP-115/107 antibody induced proteinuria 818Shunt
oxidant stress of hexose monophosphate (abst) 396Sickle cell anemia
nonsteroidal antiinflammatory drugs (abst) 178Signalingpathways in PAF (abst) 161Ca, chloride channel activation (abst) 162
Simian virus 40 (abst) 151
Single nephron GFR, micropuncture 855SK&F 101926 VI antagonist (abst) 269Skeletal muscle
CRF, PTH and fatty acids oxidation 555SLE renal activity, C3 levels (abst) 328Sodium
aldosterone on acidification (abst) 401alpha adrenergic stimulation (abst) 388ambystoma diluting segment (abst) 419ANF in regulation of excretion of (abst) 284ANP and urinary excretion in CRF (abst) 373ANP inhibits 22Na in IMCD (abst) 291aromatic L-amino acid decarboxlyase (abst) 252bicarbonate reabsorption to feeding and gavage (abst) . . . 404binding, UMR-106 cells (abst) 400concentration, Na-K ATPase 02 consumption (abst)... 426cotransport with H in BBM (abst) 178dependent uptake of Pi, phosphonoformic acid (abst) . . . 344dependent phosphate uptake (abst) 155distal acidification, acidosis (abst) 194DOCA treatment on urinary prostaglandins 930endocytosis and, cotransport in LLC-PK1 cells (abst)... 161flux, Ca (abst) 421glucocorticoid isoreceptor (abst) 170glucocorticoid isoreceptor lB (abst) 171
glucocorticoids regulate absorption (abst)growth hormone induced retention (abst)H exchange, PTH (abst)hydrogen exchange in BBMV (abst)inhibition, protein kinase C (abst)intracellular in diabetes, role of glucoseL-triiodothyronine, H exchange (abst)lithium clearance in man and dog (abst) 1034
loading in hypoproteinemia (abst) 1034loading, release of ANP (abst) 265mitotic response to high protein intake 662NaC1 reverses renal failure (abst) 364phosphate cotransport (abst) 342pump, K leak, volume regulation (abst) 418renal disease and development of hypertension, DahI
rat 1119risk of rapid treatment of hyponatremia (abst) 210selective breeding for renin response to, diet (abst). . . . 278
sensitive BP, family history of hypertension (abst) . . . . 293taurocholate in CCT 782transport by aldosterone and arginine vasotocin
(abst) 283transport in brain (abst) 191transport in uremic RBC (abst) 372tubular reabsorption, All (abst) 129
uptake, tight junction and membrane fluidity (abst).... 156varying chronic intake, ANP (abst) 285
Sodium bicarbonateexcretion of NH4HCO3 by alligator kidney (abst) 408symporter in PCT, chronic metabolic acidosis (abst)... 405
Sodium chlorideacidemia, hypertrophy (abst) 157ANF adaptation in fish (abst) 289Ca and Mg flux (abst) 348comparison of excretion in male/female rats (abst) . . . . 429hormone effects on permeability (abst) 425hypercalcemia inhibits reabsorption (abst) 424osmotic water permeabilities, vasopressin (abst) 280
Solitary kidneyCRF in (abst) 206
Somatostatinglomerular hyperfiltration, Pi (abst) 279inhibition of AVP-induced cAMP 536
Sorbinil, All receptors (abst) 380Sorbitol
aldose reductase maintain medullary intracellularmilieu 635
Splenectomy, ischemia (abst) 362Staphylococcus areus
exit site infections in CAPD (abst) 243Stenosis
transluminal angioplasty (abst) 230Steroid, ablation (abst) 377Stone
animal protein rich diet and formation of (abst) 335chlorthalidone promotes mineral retention 1140disease in Saudi Arabia (abst) 213formers, THP (abst) 342hypercalciuric, formers and vitamin D (abst) 343modulation by Ca of urinary inhibitors 1005
Streptococcal proteinase, GBM (abst) 311Stress, digitalis receptor (abst) 304Structure, kidney, standard nomenclature 1
Subclavian vein stenosis, HD 1156Subline of WKY rat (abst) 300Substrate deprivation, injury (abst) 362Sulindac
habu snake venom (abst) 310Superoxide in cuprophane membrane (abst) 224Superperfusion, isolated tubule 1009Survival
hyponatremia, sexual difference in (abst) 180Systemic lupus erythematosus
B-cell interleukin-2 (abst) 334circulating DNA 487Clq binding IgG (abst) 333C3b receptor activity (abst) 760pathogenic role of membrane protein (abst) 317
T cellactivation pathway, CsA (abst) 453antigen secreting epithelial cells (abst) 317crossmatch pretransplant (abst) 138immunization and graft rejection (abst) 135
416256298430419792177
Subject Index: Vol. 33 lxvii
increased free cytosolic Ca2 in lymphocytes (abst) . . . 292streptozotocin, gamma interferon (abst) 312vitamin D3, 112 mRNA accumulation (abst) 346
T lymphocytecellular immunoregulation, IgAN (abst) 134signal transduction (abst) 454SSN (abst) 314
T suppressor inducer cells (abst) 450TACurea, time, schedules 24:S-105Tamm-Horsfall glycoprotein
calcium stone formers (abst) 342pregnancy (abst) 203
Taurine deprivation (abst) 432TCA cycle and CRF (abst) 624Technetium-thallium scanning (abst) 1041
Terminal complement pathway (abst) 316Theophylline
hypoxemia induced renal hemodynamic changes 1078inARF 24
Thermal energy balance in HD (abst) 235Thiazides
Ca absorption 954Thick ascending limb
ammonium ion absorption (abst) 400L-thyroxine (abst) 362
Thin decending limb of Henlevunerability in isolated perfused kidney (abst) 360
Thin membrane nephropathy (abst) 137Thiola therapy, cystinuria (abst) 758Thrombin
DNA synthesis (abst) 172platelet derived growth factor regulation by (abst) 148
Thrombosishypertension in neonate (abst) 145
Thromboxanerelease, artificial membrane after blood exposure... . 24:S-75responses to angiotensin (abst) 308synthetase antagonist in progressive renal disease 77
Thromboxane A2immune complex glomerulonephritis (abst) 315
Thromboxane B2cyclosporine A (abst) 254
Thymidine incorporation and ATP (abst) 389Thymocytes, cation transport (abst) 371
Thymosinanti-influenza antibody in HD (abst) 208
Thyroid hormone, gentamicin (abst) 356
Tight junctionopening, membrane fluidity, Na uptake (abst) 156
Tissue factor synthesis (abst) 327
Toxicityamphotericin B (abst) 360CyA, Ca and protease restriction (abst) 359electrophysiology of PT cells 508gentamicin and necrosis 84low molecular weight protein (abst) 365mitochondrial, cephalosporin antibiotics (abst) 368
Toxincoagulation defects in uremia 24:S-l3extracorporeal treatment of intoxications 735uremic 24:S-4
Training, clinical competence 608
Transcutaneous gas monitoring (abst) 215
Transfusion, Tx production (abst) 258Transluminal angioplasty, HD (abst) 230
cadaver donor age and survival of graft (abst) 450cardiac, ANP response (abst) 259combined liver-kidney, oxaluria (abst) 209coronary artery disease (abst) 136CsA pharmacokinetics (abst) 445CsA, prednisone and AZA in cadaveric (abst) 440damaged kidneys in living donor (abst) 146diabetic kidney prognosis (abst) 441donor specific transfusion (abst) 258DST vs. CsA (abst) 444eterminant of graft survival (abst) 444factors influencing function (abst) 454fractional excretion of Na, effect of CsA (abst) 451glutathione transferase in urine 571
graft loss caused by cyclosporine (abst) 146heroin associated nephropathy (abst) 442HLA-A2 recognition (abst) 446in USA not fair (abst) 446long term course of CsA-associated nephropathy 590long term predictors of graft survival (abst) 448magnetic resonance imaging (abst) 1040mononuclear cells and heart graft survival (abst) 445mucosal immunity (abst) 329myelofibrosis (abst) 447omega-3 polyunsaturated fatty acids (abst) 456oral bioavailability of CsA (abst) 455parathormone levels (abst) 452pediatric, CsA converted to AZA (abst) 445
percutaneous procedures (abst) 1040
physical working capacity, uremia (abst) 758rHuEPO and erythropoiesis (abst) 452serum 11-2 activity (abst) 453successful pregnancy (abst) 441T cell crossmatch (abst) 138
triple drug therapy in pediatric (abst) 447tubular function and CsA (abst) 444
urinary antigen (abst) 440urinary calculi (abst) 336vitamin D metabolites (abst) 623
Transportactive urea, proton gradient (abst)aldosterone and ADH (abst)aldosterone and arginine vasotocin regulate Na
(abst)ambystoma PT, Cl- linked to Na (abst)amino acid (abst)amino acid uptake (abst) 417
BBM glucose (abst) 431
benzodiazepines (abst) 431bicarbonate in CT (abst) 387Ca increases Na in BBM (abst) 423
CAPD, proteins and dextrans (abst) 1038CCK-8 (abst) 138chloride, adenosine released (abst) 270Cl channel blocker (abst) 416
Transplantationadult kidney in juvenile (abst)adult liver, RF (abst)alternate day prednisone therapy (abst)anti-T cell therapy and rejection (abst).ARF after, perfused allograft (abst)Beta blockade (abst)blood transfusions critical (abst)bone mineral content (abst)Brown Norway rats (abst)
757202449447450297455756
437283
283423432
Subject Index: Vol. 33 lxiii
Plasminogen activatoractivity 868endothelial (abst) 176inhibitor (abst) 330vasoactive (abst) 157
Plasticizers, scierosing (abst) 624Platelet activating factor
All causes formation of (abst) 278calcium channel blockade (abst) 413mesangial cell synthesis (abst) 273microcirculatory responses (abst) 260multiple signaling pathways (abst) 161
permeability to proteins (abst) 280role in endotoxemic ARF (abst) 358vascular smooth muscle cells (abst) 171
Platelet activation in HUS 107Platelet arginine vasopressin
AVP in diabetes (abst) 180Platelet derived growth factor
EGF stimulate prostanoid synthesis (abst) 162Platelets, calcium in (abst) 300Plethysmography in HD (abst) 228PMN-leukocytes, transplantation (abst) 455Poison
teatment of overdose 735uremic toxins 24:S-4
Poly-L-lysine, eicosanoid (abst) 282Polyamide hemofilter (abst) 237Polyanion, heparan sulfate 517Polyaspartic acid, gentamicin (abst) 353Polycystic kidney disease
cystic kidneys 610experimental, tubular originated renal changes 8tissue culture (abst) 191
Polyelectrolytes in peritoneal dialysis 925Polyethylene glycol, injury (abst) 364Polyglobulism and CsA (abst) 452Polymeric IgA in IgAN (abst) 137Polymorph superoxide production (abst) 248Polymorphism, IgA GN (abst) 330Polymorphonuclear granulocytes (abst) 625Polymorphonuclear leukocytes (abst) 369Polysulfone
high flux dialysis membrane (abst) 239Potassium
adaptation, aldosterone (abst) 427aldosterone and kaliuresis after loading of (abst) 1037aldosterone role in high intake (abst) 270ammonia production by PT (abst) 405
225
hyperglycemia (abst) 214hypertensive injury (abst) 307mechanism of adaptation (abst) 418mechanism of aldosterone induced increase (abst) 429multiple pathways for transport (abst) 429permeability precedes injury by HgCl2 (abst) 354
permeability, uranyl nitrate (abst) 354plasma renin activity directly related to (abst) 288reversible Cl dependent flux (abst) 429stretch-activated channels (abst) 425vaspressin enhances secretion of (abst) 426
Potential, measurement of BM (abst) 420Predictors of GN outcome (abst) 143Prednisolone
conversion to alternate day therapy (abst) 449glomerular permeability to proteins in NS 1169
PregnancyANF plasma concentrations in (abst) 140ANF, aldosterone and plasma volume (abst) 257chorionic gonadotropin (abst) 260hypertension and plasma renin activity (abst) 306IgA glomerulonephritis (abst) 136
membranous glomerulonephritis (abst) 132renal functional reserve (abst) 206successful in transplant recipients (abst) 441successful outcome, hemodialysis (abst) 132Tamm-Horsfall glycoprotein excretion (abst) 203
Pressor effects on GBM (abst) 295Prevention, progression of renal disease 116Procoagulant
activity of macrophages in GN (abst) 130activity in GN (abst) 134in remnant kidney (abst) 384
Procollagen mRNA, nephrectomy (abst) 370Progressive glomeruloscierosis
chronic serum sickness (abst) 1037Progressive renal disease
rational therapeutic principles 116Progressive renal failure
new antibody-antigen system (abst) 333'251-iothalamate clearance, creatinine (abst) 190
Propionate, cell swelling (abst) 418Prostacyclin production, cAMP (abst) 271
Prostaglandinammoniagenesis in acute respiratory alkalosis (abst)... 401ANF antagonizes release of (abs) 279blockade in denervated kidneys, captopril (abst) 277cAMP and Ca2 signaling systems (abst) 271
Ca2, bradykinin in arterioles (abst) 261DOCA salt treatment on urinary 930GFR, albumin in diabetes (abst) 199glomerular production, GN (abst) 264glucagon, mediates amino acid induced rise in
hemodynamics 1147
hydronephrotic kidney sensitivity to bradykinin 71
hydroxyeicosatetraenoic acids (abst) 265interleukin-l induces natriuresis 1059mesangial cell proliferation, matrix synthesis (abst). . . . 268modulate mesangial cell proliferation (abst) 276Na-K ATPase activity (abst) 417PTH mediated Ca transients (abst) 351
vasopressin antagonists (abst) 251
verapamil, GFR and CyA administration (abst) 355
Prostaglandin E1reversal of proteinuria (abst) 321
Prostaglandin E2cytoprotective effects of (abst) 281
epidermal growth factor mechanism (abst) 274inhibits Na-K-ATPase in IMCD (abst) 268production in diabetic rats with hypertension 1100renal denervation, natriuresis (abst) 280
bath, dialysis (abst)Cail channels in mesangial cells (abst)cell rubidium uptake indexes transport ofchannels in papillary surface epithelium (abst).C1 channel currents in BLM (abst)conductance, muzolimine (abst)depletion alkalosis, PHCO3 (abst)depletion and vasopressin (abst)depletion causes Na retention, high BP (abst)depletion, metabolic acidosis (abst)
164642424428424402431299405
Subject Index: Vol. 33 lxix
vitamin D3 in parathyroid glands (abst) 335zinc balance, zinc deficiency in 1091
Uremiclindane (abst) 199
nephropathy, insights (abst) 334PTH on lymphocyte in (abst) 197
Ureteral excision in rat (abst) 437Ureteral obstruction (abst) 358
management of complications during transplantation(abst) 1040
Urinary abnormalities in CRF (abst) 375Urine
acidification, proton translocating ATPases 767alkali secretion (abst) 399culture of cells, ATN (abst) 364glutathione transferase in the 571nitrogen and phosphate excretion and body mass index
(abst) 383Uroarthritis (abst) 761Urokinase
plasminogen activator (abst) 176
protein kinase (abst) 170Urosepsis, endotoxemia (abst) 212
Valsalva maneuvereffect on ANF release (abst) 269
Vanadate, H-ATPase (abst) 394Vancomycin therapy in CAPD (abst) 136Vascular reactivity, hypertension (abst) 305Vascular smooth muscle cells (abst) 303
desensitation to PAF (abst) 171down regulation of All (abst) 288
Vasculitisrisk factors (abst) 213spectrum if idiopathic renal (abst) 214
Vasoactive agents, adhesion (abst) 157Vasoactive intestinal polypeptide (abst) 288Vasoconstriction
alpha2 adrenoceptor (abst) 414PAF, microcirculatory response (abst) 260
VasopressinAVP in idiopathic nephrotic syndrome (abst) 211BP changes in hypertension (abst) 294Ca and cAMP as second messengers (abst) 286Ca and Na transport (abst) 417dehydration and rehydration (abst) 141demeclocycline effect on cAMP (abst) 252dialysis hypotension (abst) 222energy metabolism (abst) 255genetic linkage, diabetes and DNA marker (abst) . . . . 1035lithium effect on water flow (abst) 263luminal pH effects on K secretion (abst) 426NaC1 and osmotic water permeabilities (abst) 280neuropeptide Y inhibition (abst) 252oxytocin binding sites 959pertussis toxin, Vl receptor (abst) 257phorbol myristate acetata, A23 187 (abst) 252phosphoinositide hydrolysis in LLC-PK1 cells (abst).... 161renal hypertrophy (abst) 264renal prostaglandins (abst) 251resistance to, K depletion (abst) 431selectivity contracts arterioles (abst) 262sensitive cAMP metabolism by Ca (abst) 268sytosolic Ca, LLC-PK2 cells (abst) 289water channel in endocytic vesicles (abst) 175
action, pertussis toxin (abst) 264
enhances K excretion (abst) 426Vein stenosis, subclavian, HD 1156
VerapamilCa absorption (abst) 343CsA interaction (abst) 449PBM and CsA (abst) 455
Vesicoureteric reflux in children (abst) 179Vimentin filament in glomerulus (abst) 134Vitamin B6 deficiency, azotemic (abst) 388Vitamin C supplementation (abst) 382Vitamin D
experimental uremia (abst) 334keto acids in osteodystrophy (abst) 132metabolites after transplantation (abst) 623
Vitamin D3atherogenic role of (abst) 347clearance of calcitriol in ARF 530cytosolic Ca in parathyroid cells (abst) 349cytosolic calcium in parathyroid cells 850essential hypertension (abst) 627hypercalciuric stone formers (abst) 343increases plasma Al in RD 24:S-175interleukin 2 accumulation in T cells (abst) 346phosphorus levels regulated (abst) 346Pi transporter (abst) 350preventing bone disease 24:S-178prevents parathyroid cell proliferation (abst) 344PTH and CRF 1049synthesis and activity of analogs of (abst) 339synthesis in metabolic acidosis (abst) 342
Voltagedependent Cl channel (abst) 422
VolumeCa dependency of hypotonic regulation (abst) 436cell, ADH regulates (abst) 427hypotonic cell, cyclosporine (abst) 368peritoneal dialysate measurements 64regulation in PT (abst) 428regulation, Na pump, K leak (abst) 418regulatory cell decrease (abst) 439regulatory increase, CCT (abst) 436
Vi receptor antagonist (abst) 269
Waterchannel, vasopressin inducible (abst) 175
flow, energy metabolism during vasopressin (abst) .... 255
treatment in dialysis (abst) 223vesicles deliver conducting particles (abst) 261
Wegener' s granulomatosisdialysis and transplant (abst) 1035serological diagnosis of (abst) 760
Xanthine oxidase deficiency (abst) 208
Zincbalance in uremia and zinc deficiency 1091depletion, vitamin D3, phosphate diet (abst) 342
l-deamino-8-D-arginine-vasopressincorrects bleeding in uremia (abst) 142diabetes insipidus (abst) 182
1 ,25-dihydroxycholecalciferolbone turnover during treatment with phosphate
binders 98912-Lipoxygenase, All, Cai (abst) 173
lxx Subject Index: Vol. 33
125 1-iothalamate, RF (abst) . 1901251-SCH23982, DA-1 receptor (abst) 41914, 15-Dihydroxyeicosatrienoic acid
AVP induced conductivity in CCD (abst) 26715-deoxyspergualin (abst) 322
HN (abst) 32415N glutamine metabolism, Fanconi (abst) 39315N, ammoniagenic pathways (abst) 16716-dimethyl prostaglandin E (abst) 4522-bromoethylamine hydrobomide (abst) 367
24,25(OH)D3blunts hypercalcemic effect in CR1 (abst) 347hypercalcemic effect of I ,25(OH)2D3 (abst) 347
29-Nor-aldosterone, excretion (abst) 2733H-metolazone binding, thiazide (abst) 41531P nuclear magnetic resonance (abst) 397
hyponatremia (abst) 1785'-nucleotidase, ischemia (abst) 39699m-technetium-pertechnetate (abst) 41699mTc-DMSA, renal handling (abst) 1034